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Recent reports suggest that a polymorphism of the alpha-actinin-3 gene (ACTN3) 
is associated with muscle power.  Homozygosity for the R577X single nucleotide 
polymorphism (SNP) at the ACTN-3 gene locus results in the absence of ACTN-3 
expression.  To examine the influence of this polymorphism on baseline peak power (PP) 
and PP changes with strength training (ST), we studied 53 older men (64 (9) yr) and 65 
older women (65 (9) yr) before and after a 10-week single leg knee extension strength 
training (ST) program.  At baseline, when men and women were combined, the XX 
group had a relative PP (tested at 70% of 1 RM) that was 36 ± 17 watts (W) higher than 
the RR group (279 ± 12 W, P < 0.05), and the RX group was 43 ± 17 W higher than the 
RR group (P < 0.05), when age and sex differences were used as covariates.  As a result 
of the ST program, change in absolute PP in the RR group was significantly higher than 
in the XX group (48 ± 7 W vs. 26 ± 7 W, P < 0.05), when the data were adjusted for age, 
 
sex, and changes in the untrained leg.  Separate analyses by sex found that in women the 
XX group had a significantly higher baseline absolute PP than the RR (240 ± 11 W vs. 
208 ± 9 W) and RX groups (240 ± 11 W vs. 208 ± 10 W, both P < 0.05), when age and 
baseline fat-free mass were covaried.  The change in absolute PP in the RR group was 
significantly higher than in the XX group (63 ± 14 W vs. 25 ± 9 W, P < 0.05) with ST in 
men, when the data were adjusted for age and changes in the untrained leg.  There were 
no differences among genotype groups in women for change in absolute PP.  These 
results suggest that the ACTN3 R577X polymorphism may influence peak power at 
baseline and in response to ST in older adults, but this relationship is strongly dependent 
on the sex of the group studied. 
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 INTRODUCTION 
 The loss of muscle mass, strength, and power with advanced age (sarcopenia) is 
associated with dysfunction and poor health status in older adults (140, 141).  For this 
reason, interventions designed to prevent and treat of sarcopenia should positively affect 
muscle mass, strength, and power without adverse side effects.  The administration of 
growth hormone and testosterone have been recommended for this, but the efficacy and 
untoward side effects of these agents have been questioned (18).  Therefore, strength 
training (ST) is becoming the intervention of choice for sarcopenia due to the substantial 
evidence for its efficacy and safety (77, 148).  However, muscle mass and strength 
responses to ST vary widely even among people of similar characteristics performing the 
same training program (26, 81).   
 ST-induced changes in peak power and movement velocity are also highly 
variable in older adults.  For example, we have recently observed changes in peak power 
with ST of the knee extensors for men and women ranging from – 19 to 126 W at the 
same absolute resistance, and peak movement velocity changes ranging from -1.1 to 2.7 
rad/sec at the same absolute resistance (37).  Additionally, in a previous investigation 
from our laboratory, we found considerable inter-individual variability in muscle quality 
(MQ, strength per unit of muscle) (81).  These large inter-individual differences among 
older men and women, along with the fact that twin studies suggest that a major portion 
of the variance in skeletal muscle phenotypes can be accounted for by heredity (6), 
suggest that genetic factors may explain a large portion of these inter-individual 
differences in responses to ST.  However, polymorphisms within specific genes that 
could potentially explain the genetic differences between responders and non-responders 
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 to a ST intervention have not been clearly identified.  Obtaining this information would 
have important clinical implications because it could aid in identifying the optimal 
manner of stratifying ST to those who benefit the most and least in each component 
(muscle mass, strength, and muscle power) of sarcopenia.   
 Recent reports have suggested that a polymorphism of the alpha-actinin-3 gene 
(ACTN3) may be associated with muscle power and may at least partially explain the 
inter-individual variability in power (198).  Alpha-actinins (ACTN) are cytoskeletal 
proteins that are encoded by the spectrin superfamily genes and are present in both non-
muscle and muscle tissues.  They are the primary constituent of the Z-disks in skeletal 
and cardiac muscle (39).  The function of ACTN heterodimers is to cross-link and bind 
with actin, along with preserving a spatial association among myofilaments (119).  While 
ACTN-2 expression occurs in all skeletal muscle fiber types, ACTN-3 expression is 
restricted to type 2 fibers (131). 
      A single nucleotide polymorphism (SNP) has been identified in exon 16 of the 
ACTN-3 gene and is associated with a complete absence of ACTN-3 protein (131).  This 
SNP is a C to T transition at position 1,747, which causes a change in the 577 amino acid 
residue from arginine, resulting in a premature stop codon (R577X) (131).  
Homozygosity of 577X results in an absence of ACTN-3 protein, although the 
individuals affected appear phenotypically normal.  Approximately 19% of Caucasians 
are ACTN-3 deficient, indicating that this SNP is a common polymorphism among this 
racial group (119).  The absence of ACTN-3 due to the X-allele of the R577X SNP has 
raised questions regarding its potential effects on muscle function and athletic 
performance.  In this regard, recent cross-sectional data suggest that a deficiency of 
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 ACTN-3 is associated with an enhancement of athletic power performance (202).  Elite 
power athletes, such as sprinters, have a significantly lower X-allele frequency than other 
types of athletes or controls (129, 198).  Recent ST data with younger adults showed that 
women who are X homozygotes have lower baseline isometric arm strength compared to 
heterozygotes, but had significantly greater increases in strength compared to 
heterozygotes, and displayed additive effects when all three groups were compared (31).  
However, we are not aware of any information available on the influence of the ACTN3 
R577X polymorphism on peak power and peak movement velocity responses to ST in 
older adults.  These components of sarcopenia may be even more important than strength 
for influencing functional abilities in the elderly (34).  Therefore, the purpose of this 
study was to determine the influence of the ACTN3 R577X polymorphism peak muscle 
power at baseline and in response to ST in older adults.  We hypothesize that women X 
homozygotes will have lower knee extensor absolute peak power at baseline when 
compared to the RR and RX genotype groups, but the increase in absolute peak power 
with ST will be greater in the X homozygotes than in the RR and RX genotype groups. 
 
METHODS 
Subjects.  One-hundred fifty-one relatively healthy, inactive, Caucasian men and 
women volunteers between the ages of 50 and 85 yrs were recruited as subjects in this 
study.  All subjects underwent a phone-screening interview, received medical clearance 
from their primary care physician and completed a detailed medical history prior to 
participating in this study.  All subjects were nonsmokers, and were free of significant 
cardiovascular, metabolic, or musculoskeletal disorders that would affect their ability to 
safely perform heavy resistance exercise.  Subjects who were already taking medications 
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 for at least three weeks prior to the start of the study were permitted into the study as long 
as they did not change medications or dosages at any time throughout the study.  After all 
methods and procedures were explained, subjects read and signed a written consent form, 
which was approved by the Institutional Review Board of the University of Maryland, 
College Park.  All subjects were continually reminded throughout the study not to alter 
their regular physical activity levels or dietary habits for the duration of the investigation, 
and body weight was measured weekly throughout the study to help confirm compliance 
to maintaining a stable diet. 
Genotyping.  Genomic DNA, isolated from white blood cells, was prepared from 
EDTA-anticoagulated whole blood samples by standard salting-out procedures (Puregene 
DNA Extraction, Gentra Systems Inc.).  Genotyping for the ACTN3 R577X 
polymorphism was carried out following the procedures described by Mills et al. (119).  
Briefly, DNA was amplified via polymerase chain reaction (PCR) using flanking primers 
designed specifically for the R577X polymorphism.  A restriction fragment length 
polymorphism (RFLP) procedure was used to identify genotypes for each subject at this 
locus.  PCR was performed by 40 cycles of denaturation at 94°C for 30 sec, annealing at 
58°C for 30 sec, and extension at 72°C for 30 sec, and a final extension step of 72°C for 5 
min.  The amplified fragment subsequently underwent digestion by Dde I.  Agarose gel 
electrophoresis was then performed using a 3% gel at 150V.  Digested products were 
stained with ethidium bromide, and then examined under UV light for genotype 
identification. 
Body Composition Assessment.  Body composition was estimated by dual-
energy x-ray absorptiometry (DXA) using the fan-beam technology (model QDR 4500A, 
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 Hologic, Waltham, MA).  A total body scan was performed at baseline and again after the 
ST program.  A standardized procedure for patient positioning and utilization of the QDR 
software was used.  Total body fat-free mass (FFM), fat mass, and % fat were analyzed 
using Hologic version 8.21 software for tissue area assessment.  Total body FFM is 
defined as lean soft tissue mass plus total body bone mineral content (BMC).  The 
coefficients of variation (CV) for all DXA measures of body composition were calculated 
from repeated scans of 10 subjects who were scanned three consecutive times with 
repositioning.  The CV was 0.6 % for FFM and 1.0% for % fat.  The scanner was 
calibrated daily against a spine calibration block and step phantom block supplied by the 
manufacturer.  In addition, a whole body phantom was scanned weekly to assess any 
machine drift over time. 
Body weight was measured to the nearest 0.01 kg with subjects dressed in 
medical scrubs, and height was measured to the nearest 0.1 cm using a stadiometer 
(Harpenden, Holtain, Wales, UK).  Body mass index (BMI) was calculated as weight 
(kg) divided by height (m) squared. 
Muscular Strength.  One-repetition maximum (1 RM) strength tests were 
assessed on the knee extension exercise before and after the ST program using an air-
powered resistance machine (Keiser Sports/Health Equip. Co., Inc., Fresno, CA).  This 
exercise was chosen because it could easily be tested in a standardized way using 
objective criteria.  The 1 RM test was defined as the maximal resistance that could be 
moved through the full range of motion with proper form one time.  Approximately the 
same number of trials (6-8) and the same rest periods between trials (~ 1 min) were used 
to reach the 1 RM after training as before training.  Before the regular ST program, 1 RM 
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 testing, and power testing were performed, subjects underwent at least two 
familiarization sessions in which the participants completed the training program 
exercises with little or no resistance and were instructed on proper warm-up, stretching 
and exercise techniques.  These low-resistance training sessions were conducted in order 
to familiarize the subjects with the equipment, to help control for the large 1 RM strength 
gains that commonly result from skill (motor learning) acquisition during the initial 
stages of training, and to help prevent injuries and reduce muscle soreness following the 
strength testing protocol.  The same investigator conducted strength tests for each subject 
both before and after training using standardized procedures with consistency of seat 
adjustment, body position, and level of vocal encouragement.  When appropriate, straps 
and/or belts were used to stabilize the subject so that recruitment of outside muscle 
groups was minimized.  The 1 RM was achieved by gradually increasing the resistance 
from an estimated sub-maximal load after each successful exercise repetition until the 
maximal load was obtained. 
Muscle Volume.  To quantify quadriceps muscle volume (MV), computed 
tomography (CT) imaging of the trained and untrained thighs was performed (GE 
Lightspeed Qxi, General Electric, Milwaukee) at baseline and during the last weeks of 
the 10-week unilateral ST program.  Axial sections of both thighs were obtained starting 
at the most distal point of the ischial tuberosity down to the most proximal part of the 
patella while subjects were in a supine position.  Measurements of MV in the untrained 
leg served as a control for seasonal, methodological, and biological variation of MV, by 
comparing the changes in the control leg to the training-induced changes in the trained 
leg.  This also has the advantage over using a separate group of subjects as controls, by 
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 controlling for attention effects and genetic differences between treatment and control 
groups.  Section thickness was fixed at 10 mm, with 40 mm separating each section, 
based on previous work in our laboratory by Tracy et al. (177).  Quadriceps MV was 
estimated based on using a 4 cm interval between the center of each section.  Each CT 
image was obtained at 120 kVp with the scanning time set of 1 s at 40 mA.  A 48-cm 
field of view and a 512 X 512 matrix were used to obtain a pixel resolution of 0.94 mm.  
Two technicians performed analyses of all images for each subject using Medical Image 
Processing, Analysis, and Visualization (MIPAV) software (NIH, Bethesda).  Briefly, for 
each axial section, the cross-sectional area (CSA) of the quadriceps muscle group was 
manually outlined as a region of interest.  The quadriceps CSA was manually outlined in 
every 10 mm axial image from the first section closest to the superior border of the 
patella to a point where the quadriceps muscle group was no longer reliably 
distinguishable from the adductor and hip flexor groups.  The same number of sections 
proximal from the patella were measured for a particular subject before and after training, 
to ensure within subject measurement replication.  Investigators were blinded to subject 
identification, date of scan, and training status, for both baseline and after training 
analysis.  Repeated measurement coefficient of variation were calculated for each 
investigator based on repeated measures of selected axial sections of one subject on two 
separate days.  Average intra-investigator CV was 1.7% and 2.3% for investigator one 
and two respectively.  The average inter-investigator CV was < 4.3%.  Final MV was 
calculated using the truncated cone formula as reported by Tracy et al. (177) and 
described by Ross et al. (147). 
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 Peak Muscle Power.  Determination of peak knee extensor peak power and 
movement velocity were performed on a customized Keiser pneumatic resistance knee 
extension (K410) machine (Keiser Sports/Health Equip. Co., Inc., Fresno, CA), 
specifically designed for muscle power assessment.  The K410 machine was equipped 
with load cell force transducers and position sensors to detect rotary motion at the joint.  
The K410 hardware was connected to a PC and used an industrial data collection 
expansion card to digitize data at 400 times · s-1 from the force sensors and position 
sensors.  This speed was configured and set by the K410 software.  Movement velocity 
assessment was derived from a crystal oscillator on the data collection board.   
Prior to testing, seated blood pressure was measured after five minutes of rest, and 
then a one-minute warm-up was performed on a stationary cycle ergometer.  Subjects 
were then positioned on the K410 with the medial condyle aligned with the axis of 
rotation of the machine arm.  Subjects were instructed to cross their arms across their 
chest, and a seat belt attached to the machine was then securely fastened around the waist 
to help isolate the knee extensor muscle group.  Subjects were instructed to perform a 
knee extension with each leg unilaterally at a resistance of ~ 30% of their measured 1 RM 
and at ~ 50% of their maximal velocity, as a warm-up trial.  Following a 30 s rest period, 
subjects performed three power tests on each leg alternating between right and left at 
50%, 60%, and 70% of their 1 RM, with a 30 s rest period between each of the three trials 
and 2 min rest periods between each increase in resistance. The tester offered 
standardized oral encouragement to each subject to extend his or her knee as quickly and 
forcefully as possible during each trial.  The highest peak power value of the three trials 
for each % of 1 RM and the highest (peak) movement velocity attained during this same 
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 trial was selected.  Although peak movement velocity was selected from the same test 
trial as peak power, it was measured separately from peak power as the highest velocity 
obtained during the trial, independent of where peak power was obtained.  The entire 
procedure was repeated 48-72 h later and the peak power values at each resistance level 
for both baseline tests was averaged in an effort to establish a more stable baseline 
assessment.  This test was repeated during the last week of the 10-week unilateral ST 
program for the after ST test.  During this latter test, an attempt was made to find a load 
that could be replicated from baseline testing that represented 50% or 60% of the after ST 
1 RM for testing at the same absolute load.  When a replicable load could not be found 
that fell at one of these relative loads (i.e., 50% or 60% of the after ST 1 RM), the load 
that was used at 50% of the baseline 1 RM value was used for the after ST same absolute 
load (regardless of the % of after ST 1 RM that the load represents) during the after ST 
test.  The 70% of the after ST 1 RM was compared to 70% of 1 RM at baseline for 
assessing the effects of training on peak power and movement velocity at the same 
relative load.  This relative load was chosen because it is the approximate load where the 
highest peak power was found at baseline and after training in our pilot data and from 
another investigation (34, 49).  Data for each repetition was passed through a zero-phase 
forward and reverse digital filter designed using MatLab version 6.0.5 (Math Works Inc., 
Natick, MA) to remove sensor noise prior to determining the peak power and movement 
velocity.  A low-pass, 10th order Butterworth filter with a cutoff frequency of 10 Hz was 
used.  A simple point-to-point search of the power and movement velocity data was 
conducted to determine the peaks because the resulting power and movement velocity 
curves were unimodal throughout a single repetition.  The power machine was calibrated 
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 daily against a standardized weight supplied by the manufacturer. The CV for the force 
and machine arm position were calculated from ~ 35 calibration data points, measured at 
evenly spaced time intervals during the duration of the study.  The CVs were < 5% for 
force at all positions and for both the right and left sides. 
Training Program.  The training program consisted of unilateral (one-legged) 
training of the knee extensors of the right leg, three times per week, for ~ 10 weeks. 
Training was performed on a Keiser A-300 air powered leg extension machine.  It 
allowed ease of changing the resistance without interrupting the cadence of the exercise. 
The untrained control leg was kept in a relaxed position throughout the training program.  
  Subjects warmed-up on a bicycle ergometer for approximately two minutes prior 
to each training session.  Following the two familiarization training sessions previously 
described, the training consisted of five sets of knee extension exercise for those < 75 yrs 
of age and four sets for those ≥ 75 yrs of age.  We did not have those ≥ 75 perform the 
last set because of our concern that performing 50 repetitions at near maximal effort for 
this age group might have caused overtraining, which has been shown to result in a 
reduction in strength gains with training (133).  The protocol was designed to include a 
combination of heavy resistance and high volume exercise.  The first set was considered 
warm-up and consisted of five repetitions at 50% of the 1 RM strength value.  The 
second set consisted of five repetitions at the current 5 RM value, which was initially 
estimated based on our previous data showing that it corresponds to ~ 85% of 1 RM in 
most people.  Adjustments were made as needed during each training session so that the 
resistance used resulted in failure to complete a 6th repetition.  The 5 RM value was 
increased continually throughout the training program to reflect increases in strength 
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 levels.  The first four or five repetitions of the third set were performed at the current 5 
RM value, then the resistance was lowered just enough to complete one or two more 
repetitions before reaching muscular fatigue.  This process was repeated until a total of 
10 repetitions were completed.  This same procedure was used in the fourth and fifth sets, 
but the total number of repetitions was increased in each set to 15 and 20 reps, 
respectively.  This procedure allowed subjects to use near maximal effort on every 
repetition while maintaining a relatively high training volume.  The second, third, fourth, 
and fifth sets were preceded by rest periods lasting 30, 90, 150, and 180 seconds, 
respectively.  The shortening phase of the exercise was performed in approximately two 
seconds, and the lengthening phase lasted approximately three seconds.  Subjects 
performed supervised stretching of the knee extensors and hip flexors following each 
training session. 
Statistical Analyses.  All statistical analyses as described below were performed 
using SAS software (SAS version 9.1, SAS institute, Inc., Cary NC). 
Tests for differences among means.  Differences in means for baseline variables 
among genotype groups were determined using three level two-way analysis of 
covariance (ANCOVA), covarying for age, body mass, height, BMI, percent fat, fat free 
mass, and medication use where appropriate for the model.  The use of medications was 
classified into the following categories:  diuretics, ACE inhibitors, hormone replacement 
therapies (HRT), and anti-inflammatory/pain reducers.  These categories were selected 
because of their potential for having physiological effects on muscle mass.  Using the 
muscle change with training in the trained leg and the change or drift in the control leg 
during this same time period (for power and velocity data), as the dependent variables, 
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 primary hypotheses were tested by three level two-way ANCOVAs.  Adjusting (when 
appropriate in the model) for appropriate covariates including age*genotype (when age 
was centered) and sex*genotype interactions, changes were compared among the three 
levels: R homozygotes, heterozygotes, and X homozygotes for the R577X 
polymorphism.  However, these interactions were not significant and were dropped from 
all models. Analyses were also done on men and women separately following the whole 
group analyses using three level one-way ANCOVAs.  To reduce experiment-wise error 
rate, contrast comparisons for pairwise comparisons that were not pre-planned were 
analyzed only when a significant global F (P < 0.05) was found.  Because it is possible 
that several of the dependent variables were highly correlated, a multivariate analysis of 
variance (MANOVA) was conducted to determine the influence of genotype on the 
variables of interest.  Additionally, contrasts were used to determine if there was a 
dominant, recessive, or additive effect of the X allele on the primary variables.  Tests of 
normality of the data indicate that the baseline and after training values for PP and MQ 
are normally distributed in men and women (Shapiro-Wilk P > 0.05).  Although the data 
for men and women were normally distributed, the residual plots suggest that the 
variances between men and women are not homogeneous. 
Hardy-Weinberg equilibrium.  The ACTN3 genotype distribution was evaluated 
for conformity with Hardy-Weinberg equilibrium using a chi-square test using one 
degree of freedom. 
Statistical power analyses.  Statistical power for the three primary genotype 
comparisons described in the primary hypotheses were estimated for the genotype 
influence on each variable.  These analyses were performed using a standard deviation 
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 (SD) obtained from our pilot data of ~ 20 subjects, which employed the identical training 
and testing protocol, and an estimated effect size (unit difference between groups).  The 
effect size for absolute peak power change approximates the magnitude of changes in 
muscle power with aging that is associated with changes in functional ability (164).  
These estimates also assumed an attrition rate of ~ 20% during the study.  Statistical 
power for changes in baseline absolute peak power, absolute PP change, and MQ change 
a-priori was estimated to be > 0.80 with alpha set at 0.05 (in men, critical effect size 
baseline absolute PP = 110 W, SD = 79; absolute PP change = 32 W, SD = 24; MQ 
change = 1.9 kg/cm3 x 10-2, SD = 1.3; in women, baseline absolute PP = 52 W, SD = 47; 
absolute PP change = 26 W, SD = 21; MQ change =  1.6 kg/cm3 x 10-2, SD = 1.4) and 
accounting for genotype distribution.  Power calculations were based on estimations from 
previous reports (164) and our preliminary data of a genotype distribution of ~ 40%, ~ 
40%, and ~ 20% for the RR, RX, and XX genotypes, respectively.       
RESULTS 
 Subject characteristics and muscle function measures at baseline and after ST for 
men (n = 69) and women (n = 82) are shown in Table 1.  There was a significant increase 
in 1 RM strength in both men (n = 55) and women (n = 57) with ST (both P < 0.001), but 
men had a significantly greater increase than women (P < 0.05) when baseline 
differences, age, and FFM were covaried.  Muscle volume (MV) also increased 
significantly in both men (8.9 ± 1%) and women (9.0 ± 1%; both P < 0.001).  There were 
no significant changes in BMI, body weight, % body fat, or FFM in either men or women 
with ST.  There were also no significant differences by ACTN3 R577X genotype group in 
men or women at baseline for age, height, weight, BMI, % body fat, or FFM.  Moreover, 
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 there were no significant differences in these subject characteristics at baseline among 
genotype groups in men or women for the analyses of absolute peak power (n = 53, 65), 
change in absolute peak power with ST (n = 37, 43), or change in muscle quality with ST 
(n = 49, 51). 
Table 2 shows that 1 RM strength increased significantly in the trained leg in men 
(25.6 ± 2%) and in women (28.9 ± 2%, both P < 0.001) with ST, irrespective of ACTN3 
genotype.  These increases are likely reduced by our familiarization procedures 
performed prior to baseline strength testing (see methods for explanation).  Moreover, 
there were significant changes in MV in the trained leg in men and women with ST (both 
P < 0.001).  Table 2 also shows a significant increase in knee extensor absolute PP (PP at 
the same absolute resistance at both baseline and after ST) in both men (10.3 ± 2%) and 
women (15.7 ± 2 %, both P < 0.001) with ST.  However, relative PP (PP at 70% of 
baseline 1 RM and 70% of the improved 1 RM after ST) increased significantly only in 
women (10.0 ± 2%; P < 0.001) with ST (Table 2).  Table 2 also shows that there was a 
significant increase in absolute peak movement velocity (PV) in men (9.7 ± 1%) and in 
women (12.1 ± 2%, both P < 0.001) with ST.  Additionally, there was a significant 
decrease in relative PV in men (P < 0.001), but not in women.  Muscle quality increased 
significantly in the trained leg in both men and women with ST (both P < 0.001).  
Furthermore, there was a significant increase in absolute muscle power quality (MPQ) in 
women with ST (P < 0.05), but there was no significant change in men.  Finally, there 
was a significant decrease in relative PV quality in men (-17.3 ± 4%) and women (- 13.3 
± 3%) in the trained leg with ST (both P < 0.001).  The only variables that changed 
significantly in the untrained leg in men were 1 RM strength (due to the cross education 
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 effect), MQ (both P < 0.001), and absolute MPQ (P < 0.05).  The changes in 1RM, 
muscle volume, MQ, absolute PP, absolute PV, and relative PV quality in men were 
significantly different than the changes or drift in the untrained leg.  The only variables 
that changed in the untrained leg in women were 1 RM (P < 0.001) and MV (1.2 ± 0.5%, 
P < 0.01).  However, this absolute change in MV was very small and not likely to be 
physiologically meaningful.  The changes in 1RM, MV, PP, absolute PV, and MQ were 
significantly different than the changes or drift in the untrained leg in women.  The 
changes in 1RM and absolute PP with ST were greater in men than in women when 
baseline differences, age, and FFM were covaried (P < 0.05). 
Genotype results.  Due to the longitudinal design of the investigation and multiple 
variables examined within each genotype group, most of the measures have some missing 
data points.  The minimum number of subjects for any of the main variables with ST is in 
men with 13, 17, and 7 subjects for the RR, RX, and XX ACTN3 genotype groups, 
respectively (absolute PP change).  In women, the minimum number of subjects is 19, 14, 
and 10 for the RR, RX, and XX ACTN3 genotype groups, respectively (absolute PP 
change).  Chi square analysis shows that the genotype distribution of the ACTN3 R577X 
polymorphism in this cohort did not fit the expectations of Hardy-Weinberg equilibrium 
(χ2 = 4.99, P = 0.03).  Genotype distributions for the ACTN3 R577X genotype groups 
were 62 (41%), 59 (39%), and 30 (20%) for the RR, RX, and XX genotype groups, 
respectively. 
One-way multivariate analyses of variance (MANOVAs) were conducted to 
determine the influence of ACTN3 genotype on 1 RM strength, absolute PP, and absolute 
PV at baseline and in response to ST.  Significant differences were found among the three 
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 genotype groups at baseline for these dependent variables (Wilks’ L = 0.89, F (6, 218) = 
2.25, P < 0.05).  In addition, there were significant differences among genotype groups in 
changes in these same variables with ST (Wilks’ L = 0.83, F (6, 142) = 2.37, P < 0.05).  
Table 3 shows the follow up ANCOVAs to the baseline MANOVA results for 
differences in muscle function variables by ACTN3 R577X genotype group when men 
and women were combined.  The XX group had a baseline relative PP that was 36 ± 17 
W higher than the RR group (P < 0.05), and the RX group was also higher than the RR 
group 43 ± 17 W (P < 0.05) when age and sex differences were covaried.  In addition, the 
XX group had a significantly higher relative MPQ than the RR group (0.28 ± 0.11 
W/cm3, P < 0.05), and the RX group was also greater than the RR group (0.20 ± 0.1 
W/cm3 x 10-1, P < 0.05).  Furthermore, the XX group had a higher baseline relative PV 
than the RR group (0.37 ± 0.17 rad/sec, P < 0.05), and the RX group was also greater 
than the RR group (0.28 ± 0.14 rad/sec, P < 0.05).  These variables (PP, MPQ, PV) were 
strongly correlated (r = + 0.67 to + 0.83, P < 0.001), which may explain why they are all 
significantly different by ACTN3 genotype.  There were no significant differences at 
baseline between ACTN3 R577X genotype groups for 1 RM, MV, muscle quality, 
absolute PP, MPQ,  PV, or PV quality when age and sex differences were covaried 
(Table 3).  There were no age-genotype interactions for any of the analyses performed at 
baseline.   
  Because a previous report suggests that the influence of ACTN3 R577X genotype 
on muscle function may depend on what sex group is studied (31), and because sex was a 
significant covariate in the model for the variables shown in Table 3 at baseline, separate 
analyses were performed for the baseline values and training response of each sex group 
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 by ACTN3 genotype.  Table 4 shows the difference in muscle function measures by 
ACTN3 genotype in women.  There was a significantly greater baseline 1 RM in the RR 
group than in the RX group (2.9 ± 1 kg, P < 0.01) when age and hormone replacement 
therapy (HRT) were included as covariates.  In addition, the XX group had a significantly 
higher baseline absolute PP than the RR (32 ± 14 W) and RX groups (32 ± 15 W, both P 
< 0.05) when age and baseline FFM were included as covariates.  Contrasts indicate that 
there is a significant dose response (additive) effect of the X allele on absolute PP at 
baseline in women (P < 0.05).  Furthermore, the XX group had a significantly greater 
relative PP than the RR group (35 ± 14 W) and the RX group (35 ± 15 W, both P < 0.05) 
when age, baseline FFM, and HRT were covaried.  Furthermore, the XX group had a 
significantly greater relative MPQ than the RR group (0.31 ± 0.14 W/cm3 x 10-1) and the 
RX group (0.28 ± 0.12 W/cm3 x 10-1, both P < 0.05) when age and baseline FFM were 
covaried.  There were no baseline differences by ACTN3 genotype in men for any of the 
muscle function measures shown in Table 4.  Usage of ACE inhibitors, diuretics, or anti-
inflammatory medications were not significant covariates in any of the models of 
baseline muscle function measures by ACTN3 genotype group.  
 Figure 1 shows that when men and women are combined and grouped by ACTN3 
genotype, the change in absolute PP with ST in the RR group was significantly greater 
than in the XX group (22 ± 11 W, P < 0.05) with ST.  There was a trend toward 
significantly greater absolute PP change in the RR group than in the RX group (19 ± 10, 
P = 0.07) with ST, when the data were adjusted for age, sex, and changes in the untrained 
leg.  Contrasts also indicate that there is a significant dose response (additive) effect of 
the X allele on change in absolute PP with ST (P < 0.05).  There was a significant within 
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 group increase in the RR, RX (both P < 0.001), and XX (P < 0.01) groups from baseline 
with ST.  Figure 1 also shows that there was a borderline significantly greater change in 
relative PP in the RR group than in the XX group (26 ± 13 W, P = 0.05) when the data 
were adjusted for age, sex, and changes in the untrained leg.  In addition, there was a 
significantly greater change in absolute MPQ in the RR group than in the XX group (0.20 
± 0.08 W/cm3 x 10-1, P < 0.01) when the data were adjusted for age, sex, and changes in 
the untrained leg.  There were no significant differences in 1 RM, MV, MQ, PV, absolute 
MPQ, or PV quality with ST among genotype groups when men and women were 
combined. 
Figure 2 shows that in men grouped by ACTN3 genotype, the change in the RR 
group was significantly higher than the XX group (38 ± 17 W, P < 0.05) in absolute PP 
with ST, when the data were adjusted for age and changes in the untrained leg.  Contrasts 
also indicate that there is a significant additive effect of the X allele on change in absolute 
PP with ST in men (P < 0.05).  There was a significant within group increase in the RR 
group from baseline (P < 0.01), but the XX group did not increase their absolute PP 
significantly.  There were no differences in the change in the relative PP in men by 
ACTN3 genotype with ST (Figure 2).  Figure 3 shows that the increase in absolute MPQ 
with ST in the RR group was significantly higher than the change in the XX group (24 ± 
10 W/cm3 x 10-3, P < 0.05) when age and changes in the untrained leg were included as 
covariates.  In addition, there was a within group trend toward a significant increase in 
absolute MPQ in the RR group (P = 0.09) with ST, but not in the RX or XX groups.  
There was no difference between genotype groups for change in relative MPQ with ST 
(Figure 3).  There was a trend toward a significantly higher change in absolute PV in the 
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 RR group than in the XX group (2.8 ± 1.5 rad/sec x 10-1, P = 0.06).  Furthermore, there 
was a significant within group increase in absolute PV in the RR (P < 0.01) and RX (P < 
0.001) groups in men with ST, but there was only a trend toward a significant increase in 
the XX group (P = 0.09).  There were no differences among ACTN3 genotype groups for 
change in relative PV with ST.  Absolute PP, MPQ, and PV are strongly correlated (r = + 
0.77 to + 0.91, P < 0.001), which may, once again, explain why there was a significantly 
lower change in the XX group when compared to the RR group for these muscle function 
variables.  There were no significant differences in men by ACTN3 R577X genotype for 
change in 1 RM strength, MV, MQ, absolute PV quality, or relative PV quality with ST.  
In women there was a significant within group increase in muscle volume in the RR, RX, 
and XX genotype groups (all P < 0.001).  Furthermore, the increase in muscle volume 
was significantly greater in the XX group (123 ± 13 cm3) than in the RR group (88 ± 11 
cm3; P < 0.05) when age and change in the untrained leg were covaried.  However, there 
were no significant differences among genotype groups in women for changes in 1 RM 
strength, PP, MQ, PV, MPQ, or PV quality with ST.  There were no age-genotype 
interactions for any of the analyses performed with ST. 
  
DISCUSSION 
The results of the present study demonstrate for the first time, and contrary to our 
hypothesis, that increases in knee extensor peak power with ST are significantly 
influenced by ACTN3 R577X genotype in men, but not in women, such that men who are 
R homozygotes have significantly greater peak power response to ST than X 
homozygotes.  This difference was observed when subjects were tested for peak power at 
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 the same absolute load before and after ST (i.e., absolute peak power), and when this 
peak power was normalized for the entire volume of trained musculature (i.e., absolute 
muscle power quality).  Also contrary to our hypothesis, the data demonstrate that 
baseline absolute peak power in women is significantly greater in X homozygotes than in 
R homozygotes and heterozygotes.  Although these results need to be confirmed in an 
independent cohort before any definitive conclusions can be made, they do provide 
support for the hypothesis that the ACTN3 R577X genotype influences baseline peak 
power and the effectiveness of ST for increasing peak power and muscle power quality in 
older adults. 
 The finding of an ~ 15% training-induced increase in absolute peak power in men 
R homozygotes, but no significant increase in men X homozygotes, is in contrast to the 
conclusions of a previous report (31) that women X homozygotes have a greater strength 
response than heterozygotes with ST.  In that report, it was suggested that one 
explanation for ACTN3 genotype influencing strength response to ST in women, but not 
in men, could be the potential of steroid hormones in masking the effects of ACTN-3 
expression on muscle structure differences.  However, that conclusion was based on 
young adults undergoing arm training rather than leg training and for strength changes 
rather than peak power changes.  We did not observe any differences in the changes in 
muscle volume in men among genotype groups, suggesting neuromusculature adaptation 
differences as a potential mechanism for peak power differences among ACTN3 genotype 
groups in men.  Nevertheless, the specific mechanisms responsible for these findings will 
require many more studies. 
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  The ACTN-3 protein may allow skeletal muscle to have a greater capacity for the 
conduction of force at the Z line during a rapid contraction (198).  Given that ACTN-3 
expression is limited to type II fibers, those most involved in maximal force, contractile 
speed, and power production, our measurement of peak muscle power might be a better 
indicator of the influence of the ACTN3 polymorphism with ST than strength measures.  
In an earlier investigation, we found that there was significant variability in PP response 
to ST (37), and the results of the present investigation suggest that at least part of this 
inter-individual variability in men may be explained by ACTN3 R577X genotype.  Thus, 
there are likely many other unidentified genes influencing such a complex phenotype as 
muscle power.   
Our data also suggest that the increase in absolute PP with ST follows a dose-
response (additive) relationship by ACTN3 genotype, with the R allele appearing to be 
associated with the generation of greater muscle power response to training.  This is 
supported by the work of Yang et al. (197) who observed that ACTN-3 expression in 
skeletal muscle may be positively correlated with the number of R alleles present.  
Furthermore, our finding of ACTN3 genotype influencing increases in absolute peak 
power with ST at relatively low loads (~ 50% of 1 RM after training), may have 
important implications for functional abilities.  This conclusion is based on recent data 
suggesting that selected functional ability performance in older adults may be more 
dependent on peak power and movement velocity at lower external loads than high loads 
(34). 
It is unclear why baseline relative PP and MPQ were higher in the XX group than 
in the RR and RX genotype groups in women.  Data from a previous investigation found 
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 that women X homozygotes had a lower maximal isometric voluntary contraction 
strength (MVC) at baseline than heterozygotes (31).  Our results may also appear to be in 
contrast to an earlier case-control study that found no X homozygous women in a cohort 
of 35 elite women sprint athletes (198).  However, young women (~ 25 yrs) were studied 
in the first investigation and arm flexor MVC was measured, so these results are not 
necessarily generalizable to older women and to different phenotypes (strength vs. 
power) assessed in different muscle groups.  In the second investigation (198), the 
subjects were highly trained young women and these findings may not correspond to the 
muscle function values observed in older, sedentary women as were studied in the current 
investigation.  One possible explanation, although highly speculative, for our finding of 
differences in relative PP and MPQ at baseline among genotype groups in women, may 
be differences in the coactivation of the antagonist muscle groups (68), but future studies 
would be required to provide more definitive explanations for this.  The finding of a 
significantly greater increase in absolute MPQ in men R homozygotes than in X 
homozygotes with ST, further demonstrates that there are factors other than muscle 
hypertrophy that are responsible for genotype differences in peak power.  Further 
evidence for this comes from the finding that there were no significant differences in 
muscle volume change between genotype groups.  Earlier reports estimate that ~ 60% of 
the increase in muscular power with ST is due to factors other than muscle hypertrophy 
(46).  There are no data in the current study to determine what factor(s) this might be, but 
it is likely due to some neuromuscular adaptation that produces an increased peak power 
in R homozygotes without a concomitant increase in muscle mass, resulting in a greater 
increase in power per unit of trained muscle.  Although we are not aware of any data to 
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 support these genotype differences, there is support for the conclusion that increases in 
power and strength with ST in older adults can be influenced substantially by neural 
adaptations (68).  Additionally, a previous report from our laboratory showed that women 
have a significant increase in absolute muscle power quality with ST, but men do not 
(37).  However, the subjects in that study were not stratified by genotype, which might 
explain why no overall MPQ increase with ST was found in men.   
 The use of the untrained leg also adds a unique level of experimental control by 
controlling for normal drift in values due to variations in methodology, biology, season of 
the year, genetic differences between groups, and differences in attention between 
experimental and control groups.  This, in combination with our data showing that unlike 
strength there is no cross-education effect on absolute PP in men, minimizes the level of 
variance due to experimental error. 
Nevertheless, there are limitations in the current investigation.  For example, 
subjects in this investigation were trained using a moderate velocity training protocol (~ 2 
seconds during the shortening phase and ~ 3 seconds during the lengthening phase).  A 
higher velocity training protocol would likely produce greater gains in power (49).  We 
chose a ST protocol that is more commonly used, with a well-established track record for 
being safe and effective in older adults for producing substantial improvements in all the 
major components of sarcopenia (i.e., muscle mass, strength, and muscle quality, as well 
as power) (37, 81, 102, 176).  It is still not well established whether a high velocity 
training program, with a heavy enough resistance for optimal strength gains, is well 
tolerated by older subjects (44).  Another limitation was that there was a relatively wide 
range of ages.  It is conceivable that the youngest subjects in the study may have slightly 
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 different training responses than the older ones, but age was included as a covariate in our 
analyses and there were no significant age differences between genotype groups.  Finally, 
this investigation shows the relationship between only one polymorphism in only one 
gene at only one locus.  Muscle power is a complex phenotype, which is probably 
influenced by numerous genes and polymorphisms, as well as other environmental 
factors that may be interacting with these genes in unknown ways.  The limited sample 
size in the current investigation, especially when stratifying by sex, does not allow for the 
analysis of the interaction of multiple loci. 
Future studies will need to not only use much larger homogenous sample sizes, 
but will need to carefully develop research designs to accommodate the limitations of this 
study and the ones highlighted by Clarkson et al. (31).  Although there was a significant 
influence of the ACTN3 polymorphism on PP at baseline in women and with ST in men, 
there was no statistically significant sex-genotype interaction with regard to baseline PP 
or change in PP with ST.  Future studies might need to consider the magnitude of the 
influence of the ACTN3 polymorphism on this phenotype and adjust for the numbers of 
men and women to account for this difference.  Age might also be an effect modifier with 
regard to the influence of this SNP, as there are significant structural changes (e.g. loss of 
type II fibers, fiber type grouping) that occur in elderly skeletal muscle.  Although there 
was no age-genotype interaction for PP at baseline or change in PP with ST, the sample 
size in the current investigation likely limited the statistical power to detect this 
relationship.  Having enough subjects evenly distributed throughout the adult age range 
might allow for the group to be broken up into tertiles, quartiles, or even quintiles to 
make comparisons of relative changes in PP with ST regarding the R577X SNP.  In 
 24 
  25 
addition, perhaps an analysis of fiber type proportion and the relative change in strength, 
power, muscle mass, velocity, and various muscle quality measures would be a more 
sensitive model for detecting changes resulting from the presence or absence of ACTN-3 
in skeletal muscle.  Establishing the influence of the ACTN-3 R577X SNP on functional 
abilities, likely an even more complex phenotype, in elderly populations, is necessary in 
order to determine if this genotype is of importance for targeting individuals who may be 
more susceptible to the effects of sarcopenia and who may need specific interventions.  In 
addition, this technique needs to be applied to measure the peak power in other 
movements, such as upper leg extension used in the leg press exercise, as previously 
reported with average peak power (41, 49), and how these different muscle groups 
respond to ST by ACTN3 genotype.  Finally, an increased sample size is needed in order 
to study gene x gene interactions that explain a greater proportion of the variance of these 
complex phenotypes. 
 
  Table 1.  Physical characteristics at baseline and after strength training (ST) in men and women. 
 
                                          Men                       Women 
   
                              Baseline               After ST       Baseline              After ST 
 
N 69 551 82 572
Age (yr) 64 (9) -- 65 (9) -- 
Height (cm) 174.5 (6.9) -- 161.5 (6.6) -- 
Weight (kg) 85.6 (13.2) 85.8 (12.7) 72.3 (15.1) 72.5 (14.1) 
BMI (kg/m2) 27.9 (3.5) 28.0 (3.5) 27.8 (5.9) 27.9 (5.2) 
Body Fat (%) 28.4 (5.2) 28.2 (4.6) 39.4 (5.5) 39.1 (5.5) 
Fat-Free Mass (kg) 60.4 (8.4) 60.8 (7.6) 42.6 (6.5) 42.9 (5.9) 
1-RM (kg) 32.0 (8.8) 40.2 (9.5)*† 16.6 (4.5) 21.4 (5.2)* 
Muscle Volume3 (cm3) 1,756 (278) 1,913 (313)* 1,083 (197) 1,180 (209)* 
 Values are means (SD). Data presented are for all subjects with baseline and after ST measurements. 
 BMI = body mass index; 1-RM = knee extension one-repetition maximum; kg = kilograms. 
 1There were 51 subjects for weight & BMI, 49 for body fat %, 46 for FFM, 55 for 1 RM, and  
    49 for muscle volume that had both baseline and after ST values. 
 2There were 53 subjects for weight, BMI, FFM, and body fat %, 57 for 1 RM, and  
    51 for muscle volume that had both baseline and after ST values. 
 3Muscle volume of the knee extensors. 
          *Significantly different than baseline (P < 0.001). 
  †Significantly greater change than women when covarying for baseline differences, age, and  
    FFM (P < 0.05).   
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 Table 2.  Changes in 1 RM knee extensor strength, muscle volume, peak power, peak movement velocity, muscle quality, muscle 
power quality, and movement velocity quality with strength training (ST) in the trained and untrained leg in men and women.  
                  Men                                          Women  
                                                                             Trained Leg        Untrained Leg         Trained Leg      Untrained Leg 
1 RM (kg) 8.2 ± 0.5c,f,g 3.5 ± 0.6c 4.8 ± 0.4c,f 1.5 ± 0.3c
Muscle Volume (cm3) 157 ± 10c,f 3 ± 7 97 ± 7c,f 13 ± 5b
Absolute Peak Power1 (W) 47 ± 9c,e,g 13 ± 7 34 ± 5c,f - 2 ± 4 
Relative Peak Power2 (W) 23 ± 12 0.3 ± 7 21 ± 5c,e - 2 ± 6 
Absolute Peak Movement Velocity1 (rad/s) x 10-1 5.2 ± 0.8c,e 0.9 ± 1.1  5.3 ± 0.7c,f 0.2 ± 0.7 
Relative Peak Movement Velocity2 (rad/s)  x 10-1 - 4.9 ± 1.2c - 3.3 ± 1.2 - 2.0 ± 1.0 - 1.6 ± 1.1 
Muscle Quality3 (kg/cm3) x 10-3 3.1 ± 0.3c,d 2.0 ± 0.3c 2.9 ± 0.4c,f 1.2 ± 0.3 
Absolute Muscle Power Quality1 (W/cm3) x 10-3 4.2 ± 5.7 11.0 ± 4.9a 11.1 ± 4.8a - 2.1 ± 3.7 
Relative Muscle Power Quality2 (W/cm3) x 10-3 - 3.5 ± 7.4 4.2 ± 4.4 - 0.1 ± 5.2 - 4.4 ± 5.8 
Absolute Movement Velocity Quality1 (rad/s/cm3) x 10-4 0.4 ± 0.6 1.1 ± 0.7 1.3 ± 0.9 - 0.01 ± 1.0 
Relative Movement Velocity Quality2 (rad/s/cm3) x 10-4 - 4.5 ± 0.8c,e - 1.3 ± 0.7 - 5.0 ± 1.0c - 2.2 ± 1.0 
 Values are means ± SEM; W = watts; rad/s = radians · sec-1; kg = kilograms. 
 1The same absolute resistance at both baseline and after ST. 
 270% of 1-RM at baseline and 70% of the improved 1-RM after ST.    
 31-RM/Muscle Volume. 
 aSignificantly greater than baseline (P < 0.05). 
 bSignificantly greater than baseline (P < 0.01). 
 cSignificantly different than baseline (P < 0.001).  
 dSignificantly different than the untrained leg (P < 0.05). 
 eSignificantly different than the untrained leg (P < 0.01). 
 fSignificantly different than the untrained leg (P < 0.001).  
 gSignificantly greater change than the other sex when covarying for baseline differences, age, and FFM (P < 0.05). 
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 Table 3.  Baseline differences in 1 RM knee extensor strength, muscle volume, muscle quality, peak power, muscle 
power quality, peak movement velocity, and movement velocity quality in the trained leg by ACTN3 R577X 
genotype in men and women combined. 
  
 
                                                               
                     ACTN3 R577X Genotype 
                   RR                 RX                        XX 
                                                                                                          
1 RM (kg) 25.6 ± 0.6 (61) 23.3 ± 0.9 (59) 24.6 ± 1.1 (30) 
Muscle Volume1 (cm3) 1477 ± 26 (53) 1401 ± 32 (49) 1466 ± 41 (24) 
Muscle Quality2 (kg/cm3) x 10-2 1.7 ± 0.04 (53) 1.6 ± 0.04 (49) 1.7 ± 0.06 (24) 
Absolute Peak Power3 (W)  315 ± 12 (44) 331 ± 15 (47) 338 ± 13 (27) 
Relative Peak Power4 (W)   279 ± 12* (44) 322 ± 11 (47) 315 ± 15 (28) 
Absolute Muscle Power Quality3 (W/cm3)  x 10-1 2.1 ± 0.1 (38) 2.3 ± 0.1 (38) 2.3 ± 0.1 (22) 
Relative Muscle Power Quality4 (W/cm3) x 10-1 2.0 ± 0.1* (38) 2.2 ± 0.1 (38) 2.3 ± 0.1 (22) 
Absolute Peak Movement Velocity3 (rad/s) 4.7 ± 0.2 (44) 5.0 ± 0.1 (47) 5.0 ± 0.2 (27) 
Relative Peak Movement Velocity4 (rad/s) 4.0 ± 0.1* (44) 4.3 ± 0.1 (47) 4.4 ± 0.1 (28) 
Absolute Movement Velocity Quality3 (rad/s/cm3) x 10-3 3.4 ± 0.1 (38) 3.8 ± 0.2 (38) 3.5 ± 0.2 (22) 
Relative Movement Velocity Quality4 (rad/s/cm3) x 10-3   3.0 ± 0.1 (38) 3.3 ± 0.1 (38) 3.2 ± 0.2 (22) 
 Values are least-square means ± SEM (n) when covarying for age and sex; RM = repetition  
    maximum; W = watts; rad/s = radians · sec-1; kg = kilograms. 
  1Muscle volume of the knee extensors. 
  21-RM/muscle volume. 
  3The same absolute resistance at both baseline and after ST. 
  470% of 1-RM at baseline. 
 *Significantly less than the RX and XX groups when covarying for age and sex (P < 0.05). 
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Table 4.  Baseline differences in knee extensor strength, muscle volume, muscle quality, peak power, muscle power 
quality, peak movement velocity, and movement velocity quality by ACTN3 R577X genotype in women. 
                                             
                       ACTN3 R577X Genotype  
                    RR                           RX                            XX  
 
 
 
 
 
 
 
 
 Values are least-square means ± SEM (n); 1 RM = One repetition maximum; W = watts; rad/s = radians · sec-1;  
1 RM (kg) 18.4 ± 0.7 (35) 15.5 ± 0.9**‡ (29)  17.8 ± 1.2 (18) 
Muscle Volume1 (cm3) 1,146 ± 36 (32) 1,047 ± 29 (24) 1,135 ± 53 (14) 
Muscle Quality2 (kg/cm3) x 10-2 1.6 ± 0.05 (32) 1.4 ± 0.06 (24) 1.6 ± 0.08 (14) 
Absolute Peak Power3 (W)  208 ± 9 (27) 208 ± 10 (21) 240 ± 11*† (17) 
Relative Peak Power4 (W) 205 ± 10 (27) 205 ± 11 (21) 240 ± 12*†‡ (17) 
Absolute Muscle Power Quality3 (W/cm3) x 10-1 1.9 ± 0.1 (24) 2.0 ± 0.1 (16) 2.2 ± 0.1* (13) 
Relative Muscle Power Quality4 (W/cm3) x 10-1 1.9 ± 0.1 (24) 1.9 ± 0.1 (16) 2.2 ± 0.1*† (13) 
Absolute Peak Movement Velocity3 (rad/s) 4.4 ± 0.2 (27) 4.5 ± 0.2 (21) 4.7 ± 0.2 (17) 
Relative Peak Movement Velocity4 (rad/s) 3.9 ± 0.1 (27) 3.8 ± 0.1 (21) 4.2 ± 0.2 (17) 
Absolute Movement Velocity Quality3 (rad/s/cm3) x 10-3 4.2 ± 0.2 (24) 4.3 ± 0.3 (16)  4.2 ± 0.3 (13) 
Relative Movement Velocity Quality4 (rad/s/cm3) x 10-3 3.7 ± 0.2 (24) 3.7 ± 0.2 (16) 3.8 ± 0.2 (13) 
 
 
 †Significantly different than the RX group when covarying for age and baseline FFM (P < 0.05). 
 *Significantly different than the RR group when covarying for age and baseline FFM (P < 0.05). 
 **Significantly different than the RR group when covarying for age and HRT (P < 0.01). 
   MV = muscle volume; HRT = hormone replacement therapy.  
 There were no significant baseline differences between genotype groups in men. 
 1Muscle volume of the knee extensors. 
 21-RM/MV. 
 3The same absolute resistance at both baseline and after ST. 
 ‡HRT was a significant covariate in the analysis.
 470% of 1-RM at baseline. 
 FIGURE LEGENDS: 
Figure 1.  Changes in knee extensor absolute (same absolute resistance before and after 
ST) and relative (70% of 1 RM at baseline and after ST) peak power (PP) with ST by 
ACTN3 R577X genotype in men and women combined.  When covarying for age, sex, 
and changes in the untrained leg, there was a significantly greater increase in absolute PP 
in the RR group than in the XX group (*P < 0.05) and a trend toward a significantly 
greater increase than the RX group (P = 0.07) with ST.  When covarying for age, sex, and 
changes in the untrained leg, there was a borderline significantly greater increase in the 
RR group than in the XX group (P = 0.05).  Values are least-square means ± SEM. 
Figure 2.  Changes in knee extensor absolute (same absolute resistance before and after 
ST) and relative (70% of 1 RM at baseline and after ST) peak power (PP) with ST by 
ACTN3 R577X genotype in men.  When covarying for age and changes in the untrained 
leg, there was a significantly greater increase in absolute PP in the RR group than in the 
XX group with ST (*P < 0.05).  There were no significant differences in relative PP 
change among genotype groups.  Values are least-square means ± SEM. 
Figure 3.  Changes in knee extensor absolute (same absolute resistance before and after 
ST) and relative (70% of 1 RM at baseline and after ST) muscle power quality (MPQ) 
with ST by ACTN3 R577X genotype in men.  When covarying for age and changes in the 
untrained leg, there were significantly greater increases in absolute MPQ in the RR (*P < 
0.05) than in the XX group with ST.  There were no significant differences in relative 
MPQ change among genotype groups.  Values are least-square means ± SEM. 
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APPENDIX A 
 
  Research Hypotheses, Delimitations, Limitations, and Operational Definitions 
 
 
Research Hypotheses  
1.  Women X homozygotes at the ACTN3 gene locus of the R577X polymorphism 
will demonstrate significantly greater absolute peak knee extensor muscular 
power change with strength training when compared to RX and RR genotype 
groups.  
2.  Women X homozygotes at the ACTN3 gene locus of this same polymorphism 
will demonstrate significantly lower absolute peak knee extensor muscular power 
at baseline when compared to RX and RR genotype groups. 
3.  Women X homozygotes at the ACTN3 gene locus of this polymorphism will 
demonstrate significantly greater increases in muscle quality change with ST 
when compared to RX and RR genotype groups. 
4.  There will be no association in men between the ACTN3 R577X 
polymorphism and absolute peak knee extensor power at baseline or change in 
peak power with ST.   
Delimitations
1.  The scope of this study will be delimited to 110 men and women between the 
ages of 50 and 85 yrs who volunteer as study participants. 
2.  Participation in the study will be limited to healthy participants free of 
musculoskeletal or cardiovascular disease. 
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 3.  Based on previous research, subjects will be divided into three groups in 
determining the effect of this genotype.  The groupings will be based on homo- 
and heterozygosity for the R577X polymorphism. 
 
Limitations 
1.  The participants will be volunteers and not randomly selected from the general 
population.  Therefore, the results of this study cannot be generalized to 
individuals who do not possess characteristics such as age, body size, physical 
activity, etc. similar to those of subjects in the study. 
2.  Subjects will self-report many factors related to health and lifestyle such as 
physical activity habits, dietary habits, medication regimens, and medical 
conditions.  Because the accuracy of these reports cannot be verified, it is possible 
that inaccurate self-reports may occur, which could adversely affect the results of 
this study. 
3.  It will not be possible to verify compliance of factors that are not being self 
reported, but are part of what subjects are asked to do outside of training during 
the study period (e.g. maintain diet and activity patterns and not change their 
medications). 
4.  Genotypes other than the ACTN3 R577X polymorphism will not be assessed in 
the proposed study.  It is possible that the ACTN3 polymorphism effects are 
present only in the presence of a specific, but unknown, genetic background 
(epistasis). 
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 5.  Polymorphisms in the regions flanking the ACTN-3 gene will not be identified 
or assessed in the genomic material for this study.  It is therefore possible that any 
reported genotype effect is due to linkage disequilibrium between the R577X 
polymorphism and a distinct and putative polymorphism at another locus within 
the same chromosome.    
Operational Definitions:  
5-RM: Refers to the maximum amount of resistance an individual can move 
through a complete range of motion only five times. 
R577X polymorphism (ACTN-3 gene):  Results from a C to T transition at 
position 1,747, which causes a change in the 577 residue from arginine, resulting 
in a premature stop codon (R577X).  Homozygosity of R577X results in an 
absence of α-actinin-3 expression, although the individuals affected typically 
appear phenotypically normal.  Genbank accession number M86407.  
Computed tomography (CT):  A technique for assessing regional muscle size 
based on the examination of axial scans of the thigh.  Visual images are created 
from the measurement of the intensity of x-rays and analyzed to measure cross-
sectional area.  The images are based on the attenuation of x-rays as they pass 
through the body.  Attenuation scores are measured in Hounsfield units, which 
depend upon the level of absorption of emitted x-ray beams, -1000 air to +1000 
bone.  Skeletal muscle is typically 0 to 100 and adipose tissue is usually -190 to -
30. 
Dual-energy x-ray absorptiometry (DXA):  A technique for assessing whole 
and regional body composition that considers the body to be composed of three 
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 compartments: bone mineral mass, soft tissue, and lean tissue.  Tissue amounts 
are based on the attenuation of x-rays as they pass through the body. 
ACTN-3 protein:  Cytoskeletal protein that is present in both non-muscle and 
muscle tissues.  ACTN-3 is the primary constituent of the Z-disks in skeletal 
muscle and is only expressed in type II skeletal muscle fibers. 
ACTN-3 gene:  ACTN3 is located on chromosome 11 (11q13-q14), spans ~17 
kbp, and contains 21 exons. 
Muscle Power:  Calculated as the product of torque and angular velocity and 
reported in watts.  Torque is calculated by multiplying the force exerted by the 
distance from the knee joint to the force sensor (0.34925 m) and reported in N-m.  
Angular velocity is reported as rad · s-1. 
Muscle Power Quality:  Calculated as the peak muscle power (watts) of the knee 
extensors divided by the muscle volume (cm3) of the knee extensors. 
Muscle quality: Also known as specific tension or specific force is the strength of 
a muscle divided by the cross-sectional area to estimate the amount of force 
production per unit area of muscle tissue.  This has been shown to decrease with 
age and increase with resistance training. 
Muscle volume: Muscle volume will be determined by the MIPAV software and 
equations used by Tracy et al. (20).  Briefly, this involves an equation that utilizes 
the 8-10 axial thigh slices that are obtained from the CT scan. 
Sarcopenia: A condition characterized by the loss of muscle size, quality, and 
function that occurs with aging.  This typically leads to or exacerbates ailments 
such as osteoporosis and loss of functional independence. 
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 Sedentary: A description for individuals who are not physically active.  In the 
proposed study this term describes individuals who, on average, have exercised 
aerobically for less than 20 minutes per day less than 2 times per week and have 
not performed any type of regular resistance training over the past six months. 
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DXA Record 
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CT Appointment Request 
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1 RM Data Collection Form 
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 APPENDIX F:  LITERATURE REVIEW  
The following review of literature provides background information on sarcopenia, the 
use of strength training (ST) as an intervention for sarcopenia, and the role of genetics in 
influencing ST adaptations.  This review will focus on the following topics: 1) aging and 
sarcopenia, 2) the effects of aging on the components of sarcopenia, 3) the effects of 
strength training as an intervention on the components of sarcopenia, 4) variability in 
muscle size and function in response to aging and strength training, 5) heritability of the 
components of sarcopenia, 6) candidate genes for the components of sarcopenia, 7) 
ACTN-3 and the ACTN3 R577X polymorphism. 
Aging and Sarcopenia 
Sarcopenia is defined as the loss of muscle mass with aging, which subsequently 
affects performance and muscle function (146).  Sarcopenia has also been expanded to 
include other components including strength, muscle quality, and power (101, 107), but 
the primary measures of loss of muscle function are muscle strength and mass.  No sole 
factor has been identified that explains the aging-related loss of muscle size or function, 
as sarcopenia is also considered to be a multifactorial condition that occurs naturally, to 
some extent, with aging.  However, there is significant inter-individual variability in 
sarcopenia and the factors that influence sarcopenia.  Some of the major factors appear to 
contribute to sarcopenia are decreases in alpha motor neurons, motor units, protein 
synthesis, myosin heavy chain (MHC) expression, and an rise in catabolic stimuli such as 
cytokines (e.g. TNF-alpha) (28, 110, 160).   
For example, the loss of muscle neurons that is known to decline with age seems 
to have a greater affect on fast motor units (24, 38, 40, 145), which are associated with 
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 the aging-related loss in muscle strength.  However, more recent data indicate that the 
motor neuron loss with aging is not as considerable as previous reports suggested (123).  
The accompanying increase in motor unit size that is observed with senescence can be 
ascribed to this disproportionate loss of fast motor units, which are reinervated by slow 
motor units (40).  Despite the loss of fast motor units with aging, Urbanchek et al. (185) 
reported that deinervated muscle fibers account for only ~ 11% of the force difference in 
skeletal muscle between young and older adult rats. 
 In addition to the loss of fast motor units, muscle contractile protein synthesis rate 
is reduced with aging (7, 126).  Balagopal et al. (7) reported that whole body muscle 
protein (i.e. myosin heavy chain proteins (MHC)) synthesis was ~ 50% lower in the 
elderly than in the young, but whole body non-muscle protein synthesis did not exhibit 
this relationship.  Follow-up data from this group (8), indicated that mixed muscle protein 
synthesis and gene transcript levels of MHC-IIa and MHC-IIx were found to be lower 
with increasing age, but MHC-I synthesis was not different among age groups.  
Furthermore, age-related decline in MHC-IIa and MHC-IIx transcript levels were not 
reversed with ST, whereas exercise results in a higher synthesis rate of MHC-I isoform 
transcripts.  These data confirm earlier work by Welle et al. (193) who measured total 
and fractional protein synthesis in healthy, moderately active young and older men, and 
found that the fractional rate of myofibrillar protein synthesis was 28% slower in the 
older men than in the younger men.  Total myofibrillar protein synthesis via measurement 
of creatinine excretion was estimated to be 44% slower in the older subjects.  
Additionally, whole body protein synthesis was lower in the older than the younger 
group, even after correcting for total FFM.  However, not all investigations agree with 
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 this finding.  Morais et al. (122) reported that after correction for FFM, whole body 
protein turnover is not decreased in the elderly.  Despite some conflicting reports, the 
majority of the published data indicate several different interrelated factors that explain 
the aging-related loss of muscle mass and function, which has been observed in a host of 
investigations. 
Earlier reports on sarcopenia by Young et al. (200) found that quadriceps CSA 
was 23% and 33% smaller in elderly men and women, respectively, than in younger 
subjects.  These data are supported by the later work of Hakkinen and Hakkinen (67) who 
found a 27% lower mid-thigh CSA in older women when compared to younger women.  
However, these data may have underestimated the actual extent of sarcopenia due to the 
increase of connective tissue and fat infiltration into the muscle tissue that earlier muscle 
CSA measurement techniques could not detect.  More recently, cross-sectional data 
reported by Janssen et al. (85) measured muscle mass of 468 subjects from 18 – 88 years 
of age and found a decrease in muscle mass starting at ~ age 60, amounting to 1.9 and 1.1 
kg per decade in men and women, respectively.  The loss of muscle mass was greater in 
the lower extremities.  The initial amount of muscle mass and the rate of muscle loss with 
aging determine the progression of sarcopenia (110).   
Sarcopenia also has significant consequences on functional ability, injury risk, 
and mortality (5, 10, 138, 142).  Data from both cross-sectional and longitudinal 
investigations indicate that muscle function decreases with advancing age (54, 104, 105, 
115).  This decline in muscle function is due to a host of factors, including a decrease or 
unfavorable change in muscle volume, strength, contractile protein gene expression, 
metabolic properties, motor unit innervation, and loss of type II muscle fibers (107). 
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 The sequela of sarcopenia range from decreases in functional ability to increased 
mortality risk.  A number of investigations have demonstrated a relationship between 
diminished muscle strength and increased mortality rate (58, 99, 143).  Although reports 
vary, muscle mass declines with aging occur at a rate of ~ 1% - 2% per year after age 50 
(75, 157).  However, this decrease in muscle mass often goes unnoticed because of a 
concomitant increase in fat mass, which results in relative constancy in body weight.  
Muscle volume and strength reach a peak between 40 and 50 yrs of age and remain 
relatively stable until the sixth decade.  Beginning at ~ age 60, muscle strength will begin 
to decline at approximately 12 – 14% per decade and muscle mass will decrease at ~ 6% 
per decade (105).  This is equivalent to a loss of muscle function of ~ 40% by the eighth 
decade of life and often leads to disability and morbidity and possibly even mortality 
(116, 118).  Data from the New Mexico Elder Health Survey (14) found that up to 25% 
of persons under age 70 were sarcopenic as measured by muscle mass index (muscle 
mass (kg)/height) and defined as being more than two SD below the mean of the young 
referent population.  In addition, 30% of women and 50% of men over age 80 in that 
cohort were sarcopenic.  Moreover, more recent data using DXA to quantify appendicular 
skeletal muscle mass in ~ 200 women aged 64 – 93 and ~ 140 men aged 64 – 92 yr found 
that the overall prevalence of sarcopenia was ~ 23% in women and ~ 27% in men and up 
to 45% in those over age 80 (79).  
Furthermore, it has been reported that adjusted arm muscle area is a better 
predictor of mortality than BMI, which is often used as a predictor of mortality in the 
older adults (118).  Recent data from the Baltimore Longitudinal Study on Aging (BLSA) 
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 show that hand grip strength, independent of physical activity or muscle mass, is also a 
predictor of mortality (116). 
The Effects of Aging on the Components of Sarcopenia 
Declines in muscle mass with age is strongly correlated with strength, and the 
losses associated with aging (55, 144).  However, depending on the measurement method 
used, muscle mass has been shown to decline at a slower rate with aging than muscle 
strength  (113).  Although various measurement techniques have been used to estimate 
losses in muscle mass with age (e.g. ultra-sound, computed tomography scans (CT), 
magnetic resonance imaging (MRI), 40K counting, creatinine excretion, dual-energy x-ray 
absorptiometry (DXA), and hydrodensitometry), little information is available from 
direct measurement of muscle mass.  Metter et al. (116) measured total creatinine 
excretion to estimate FFM in a BLSA cohort of ~ 950 men and found that FFM loss of ~ 
33% occurs during the adult age span.  The post-mortem examination of cadavers allows 
a more direct measurement of muscle mass that overcomes certain ethical and logistical 
problems.  For example, Lexell et al. (103) employed a whole muscle post-mortem 
examination to quantify size of whole muscle, number of fibers, and fiber size to measure 
total age-related changes in muscle.  In this study, autopsied cross-sections of whole 
vastus lateralis muscle from 43 previously healthy men between the ages of 15 and 83 
years were examined.  The results showed that sarcopenia begins around 25 years of age 
and accelerates thereafter.  Furthermore, this muscle mass decline is caused mainly by a 
decrease in fiber number, with no preferential loss of any fiber type, and to a lesser 
degree by a loss of type II fiber size.  These data are supported by later work by Overend 
et al. (132) who found from computed tomography (CT) scans of the thigh muscles of 
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 young and older men that comparisons of relative leg muscle strength in these subjects 
may be misleading due to the decrease in muscle tissue associated with aging.  The 
authors stressed that appropriate measurement of muscle size and CSA need to be 
performed prior to making such comparisons.  More recently, Trappe et al. (182) found 
that in men and women each of the four muscles of the quadriceps atrophy similarly with 
aging, exhibiting a CSA that is ~ 27% lower in elderly subjects than in the younger 
subjects as measured by CT. 
Aging-related declines in muscle strength and power are related to changes in the 
number of motor units, altered muscle pennation angle, increases in connective tissue and 
fat infiltration, fiber type grouping, loss of type II fibers, and decreased expression of 
myosin heavy chain (MHC) proteins (7, 89, 94, 103).  These age associated reductions 
have been demonstrated by both cross-sectional and longitudinal studies, which have 
shown that there is a considerable loss of muscle strength beginning after the 50s for 
men, and somewhat earlier for women (104, 105).  However, investigations that examine 
aging effects often employ cross-sectional designs.  These studies have limitations when 
trying to establish cause and effect, due to confounders such as diet, physical activity, or 
generational differences when comparing subjects of different ages/generations, and these 
confounders persist to some extent even when using longitudinal data to assess age-
related changes.  Despite these methodological constraints, cross-sectional studies can 
provide some important contributions to the literature, especially when combined with 
other studies using large sample sizes.   
Kallman et al. (87) reported cross-sectional data from the Baltimore Longitudinal 
Study on Aging (BLSA), which measured grip strength in 847 men aged 20 – 89 years, 
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 and found that muscle strength is highest in the 30s and subsequently declines after age 
40 in curvilinear fashion.  After the 80s, strength declines by ~ 37%.  On the other hand, 
longitudinal analysis of the data showed that ~ 15% of the subjects over age 60 yrs 
demonstrated no strength decline during an ~ 9 year follow-up suggesting that there is 
significant inter-individual variability in strength losses.  This was followed up by 
another report from the BLSA, which found that concentric, eccentric, and isometric knee 
and elbow flexor and extensor strength declines with aging when ~ 650 men and women 
aged 20 – 93 years were examined (104).  In addition, Era et al. (42) reported the 
maximal isometric strength of five muscle groups in three groups of men in their 30s, 
50s, and 70s.  The results showed significant age-related differences between age groups 
in isometric handgrip, elbow flexion, knee extension, trunk extension and flexion strength 
that was similar to the BLSA results mentioned above by Kallman et al. (87).  Both 
studies examined strength differences over a similar portion of the adult age range.  Arm 
flexor and extensor data show that the declines in arm strength with aging are similar to 
the loss of leg strength, but start later.  Another earlier cross-sectional study by Frontera 
et al. (55), measured isokinetic strength of the elbow and knee extensors and flexors in 
200 healthy, 45 – 78 yr old men and women to examine the relationship between muscle 
strength, age, and body composition.  Peak torque about the knee was measured at 60 and 
240 degrees/s and at 60 and 180 degrees/s for the elbow.  Strength in all muscle groups in 
men and women at both testing speeds was significantly lower (15.5 – 26.7%) in the 65 – 
78 year old age group than in the 45 – 54 year old group.  However, when strength was 
adjusted for FFM, age-associated differences among age groups were not significant in 
all muscle groups except the knee extensors, when tested at the high velocity (240 
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 degrees/s).  These data support the hypothesis that age-related declines in muscle mass 
are at least partially responsible for decreases in strength.  This conclusion confirms an 
earlier report by Borges (19) who tested ~ 140 healthy men and women aged from 20 – 
70 years.  Maximum isometric and isokinetic knee extension and flexion muscle torque 
was measured at slow, medium, and faster velocities (12, 90 and 150 degrees/sec).  Both 
isokinetic and isometric torque was lower with advancing age in both sexes.  Isokinetic 
torque decreased significantly between 20 and 30 years of age in men and between 40 
and 50 years of age in women.  A significant decrease was also found between the ages 
of 60 and 70 years in both sexes.  Maximum isometric torque showed a significant 
decrease between 60 and 70 years in men and women.  Significant correlations were 
observed between peak torque and body mass, height, and body surface area.   
Cross-sectional data at the muscle fiber level provide support for these results.  
For example, Frontera et al. (57) reported a 35% reduction in type II muscle fiber force 
production in older men (~ 75 yrs) than in younger men.  This corresponds to other cross-
sectional data (178) showing 25 - 40% less power in single fibers in older women than 
young women, old men, and young men.  This investigation showed that older women 
demonstrate attenuated force production in single skeletal muscle fibers. 
These data suggest that the decline in whole muscle strength is at least partially 
caused by the decrease in the force generating capacity of individual muscle fibers.  
However, if elderly subjects are unable to maximally activate existing motor units, then 
limited force production of muscle fibers may be a limiting factor.  Maximal voluntary 
contraction with twitch interpolation provides evidence that older subjects can fully and 
maximally contract their musculature (33, 78, 90), although some report less than full 
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 activation (as low as 69%) of the musculature in older adults (169).  On the other hand, a 
recent report suggests that with sufficient attempts, elderly men can fully activate their 
elbow flexors and extensors, as well as younger men, even if an impairment previously 
existed (84).  This highlights a design flaw in many previous studies that measured 
muscle strength without providing an adequate familiarization period prior to strength 
testing. 
Longitudinal studies are not as common as cross-sectional investigations due to 
logistical difficulties and expense.  Furthermore, although longitudinal studies are also 
subject to other problems such as loss to follow-up and observations that are not often 
equally spaced, they are a preferable design for assessing the effects of aging.  Typically, 
longitudinal studies on sarcopenia report a more rapid rate of decline in strength than do 
cross sectional studies.  For instance, a study by Bassey and Harries (11) reported that in 
men and women > 65 years old, the rate of decline in strength with aging was ~ 2% per 
year.  However, a four-year follow-up on 620 survivors showed that grip strength had 
declined by 12% in men and 19% in women, and these losses were significantly related 
to age (11).  A significant decline was also found in physical activity and functional 
capacity.  These findings are supported by data reported by Sowers et al. (168) who 
found that in 712 younger African-American and Caucasian women aged 34 – 58 years, 
almost 9% of women had at least a 6% loss (> 2.5 kg) of lean mass over a three-year 
observation period.  This loss of muscle mass was associated with a greater decrease in 
physical functioning as determined by slower walking velocity and decreased leg 
strength.  Additionally, another longitudinal study by Aniansson et al. (4) found that over 
a seven-year period, between the age of 70 and 75, there was a significant decline in knee 
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 extensor, elbow extensor and flexor strength in both sexes, but a smaller decrease in 
isometric than in isokinetic strength.  Isokinetic muscle strength in the knee-extensors 
and flexors was higher in men with a higher level of physical activity than in those with a 
lower activity level.  Seven-year follow-up results showed a body mass decrease of 6% 
and a quadriceps muscle strength decrease of 10% - 22% over this period (3).  There was 
also a reduction in fast-twitch fiber area in the quadriceps during this time span.  Seven-
year follow-up data from this cohort found that in these active elderly men between 76 
and 80 yr of age, isokinetic strength for 30 degrees/s decreased significantly at a rate of 2 
– 3% per year (2).  There was also a significant increase in both type I and type II fiber 
areas, and this was interpreted as a compensatory adaptation for the loss of motor units 
with aging (2). 
These findings are supported by Rantanen et al. (139), who examined aging-
related changes in maximal isometric strength, over a five-year span in ~ 100 men and ~ 
185 women aged 75 years at baseline.  Results showed that there was substantial inter-
individual variability in the % change in strength over ~ 5 years ranging from a 4% 
increase in knee extension strength in men and women to a 16% decrease in grip strength 
in women.  Reduced grip strength was more extensive in women than men, and the more 
active men maintained their trunk extension strength better than the sedentary men.  In 
women who decreased their activity levels, the rate of decline in grip and elbow flexion 
strength was 32% and 27% respectively, which was greater than other similarly aged 
subjects who either remained sedentary or who were more active.  The more active 
women retained their knee extension strength at a higher level than the other groups. 
Those who died before follow-up tests exhibited poorer strength test results at baseline, 
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 indicating that low muscle strength might be a predictor of mortality.  Conclusions from 
these results also indicate that participation in everyday physical tasks (i.e. household 
work, walking, and gardening), which are also the most common physically demanding 
activities of older people, may be essential for maintaining strength at a sufficient level 
for functional abilities.  These conclusions are supported by other recent findings that 
examined muscle strength thresholds that are associated with compromised performance 
on ambulatory tasks.  For example, cross-sectional data from the BLSA (96) indicated 
that gait time decreases linearly with increasing knee extensor peak torque, then plateaus 
at higher strength levels (> 130 N m for normal gait, and > 190 N m for faster gait).  
More recently, another study found that subjects with isometric leg extension peak torque 
to body weight ratio < 3.0 N m/kg are at a substantial risk for impaired function chair 
rise, gait speed, and stair ascent and descent tasks (136). 
The above findings by Rantanen et al. (139) concur with more recent findings by 
Frontera et al. (54) who examined age-associated changes in skeletal muscle mass and 
function over 12 year span.  Twelve healthy, older (~ 65 yrs), sedentary men were 
examined at two time points.  Isokinetic muscle strength of the knee and elbow extensors 
and flexors showed declines from 20% to 30% at slow and fast velocities.  CT scans also 
showed an ~ 16% loss in the cross-sectional area (CSA) of the quadriceps.  Linear 
regression results showed that strength at baseline and changes in CSA over time were 
independent predictors of strength after 12 years.  Additionally, vastus lateralis muscle 
biopsies showed a 30% reduction type I fiber percentage, but no change in mean area in 
either fiber type.  The conclusions of this investigation were that a loss in muscle CSA is 
a major contributor to the decrease in muscle strength with advancing age and, together 
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 with muscle strength at baseline, accounts for ~ 90% of the variability in strength during 
the 12-year period.  This data is supported by other recent data that showed a smaller 
mid-thigh cross-sectional area and greater fat infiltration in the muscle are associated 
with lower strength (128) and functional ability in older men and women (191). 
Muscle quality (MQ) sometimes referred to as specific tension or strength per unit 
of muscle, also appears to be influenced by age.  MQ considers neuromuscular factors 
and is a precise estimate of skeletal muscle function as opposed to overall FFM.  MQ 
declines both at the whole muscle (105) and single muscle fiber level (57).  Early studies 
were conflicting, as Young et al. (200) reported no difference in MQ of the knee 
extensors of older women compared to younger controls when strength was measured 
isometrically.  In men, Young et al. (201) reported that, in contrast to the findings in 
women, older men showed a 19% lower MQ than younger men.  Lynch et al. (105) 
reported a difference in MQ in the leg musculature between young and older adults, and 
that arm muscle quality decreased to a similar extent in men compared to women.  
However, leg MQ declined approximately 20% more than arm MQ with increasing age in 
women.  Furthermore, Frontera et al. (57) studied single muscle fibers in younger and 
older men and women and found a difference in muscle fiber quality in men, with fibers 
from young men having greater capacity for force than fibers from older men.  More 
recently, cross-sectional data by Newman et al. (128) found that upper and lower 
extremity MQ decreased as age increased in a large cohort of ~ 2600 men and women 
between the ages of 70 – 79.  Therefore, the data show that MQ decreases with age, but 
the magnitude of this decline seems to depend on sex and the muscle group studied.   
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  Muscle power (i.e. the rate of performing mechanical work) accounts for a greater 
amount of the variance in physical performance than strength in older adults (16, 50) and 
deteriorates at a faster rate than strength with advanced age (10, 114, 164).  Although the 
literature is not as extensive for the examination of muscle power losses with aging when 
compared to strength, recent studies have focused on the changes in muscle power with 
aging and with exercise training.  This lack of data on muscle power and the elderly is 
partially attributable to the difficulty in safely and accurately measuring power (41).  The 
use of isokinetic dynamometers allow for power to be measured in a single muscle group 
based on peak torque, but this measurement does not consider the power needed to 
accomplish daily tasks at various external resistances and overcome speed (107).  
Furthermore, another major drawback of using isokinetic testing for muscle power 
assessment is that it doesn’t allow for the measurement of velocity, as velocity is pre-
determined by the tester and the device, instead of the subject being tested.  Finally, the 
allowable speed of movement for isokinetic devices is limited and may not reflect the 
optimal speed of movement obtained during unloaded movements in humans (107).
 In addition, elevated antagonist muscle activity in the elderly may limit the full 
movement efficiency depending on the type of muscle contraction and the movement 
velocity.  Earlier measurement of power employed vertical jumping from a force 
platform (45, 62), which functioned similar to a scale, whereby muscle power is the 
product of force (after subtraction of body weight from the vertical component of the 
ground reaction force) and the movement velocity.  However, the subject must move 
his/her body mass, which likely represents a higher than optimal external load for peak 
power production based on the force-velocity curve (107).  Furthermore, this type of 
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 measurement may not be safe for older subjects.  To address the safety concerns 
associated with power testing using a force platform, Bassey and Short (12) invented an 
apparatus that measured average leg extensor power from force against a pedal that 
accelerates a flywheel of known inertia.  However, older subjects were still required to 
use a higher percentage of their maximal power capacity because of the fixed inertia 
characteristic of the apparatus (107), but this problem has been since corrected by the 
development of a variable inertia testing apparatus (134).  More recently, Delmonico et 
al. (37) reported the measurement of peak power during a single trial, rather than average 
power throughout the range of movement in a trial.  A single maximal knee extension 
repetition was performed in older adults by using a machine equipped with load cell force 
transducers and position sensors to detect rotary motion at the joint.  Peak power is 
calculated by filtering power data points during a single knee extension trial with a 10th 
order Butterworth filter.      
 Izquierdo et al. (83) determined the optimal loads for maximal power production   
and found that peak power is maximized at 30 – 45% of peak strength for the upper 
extremity and at 60-70% for the lower extremity in middle aged and older adults.  
Furthermore, the results confirm previous data that shows that peak power decreases with 
increasing age to a greater extent than strength.  This work is supported by more recent 
data reported by Macaluso and De Vito (106) who found that maximum peak (average) 
power is obtained at ~ 60% of maximum isometric strength in both young and older 
women, and this peak power is 61% lower in the older women.  They also reported that 
power is influenced to a greater extent with aging than isometric strength.  In contrast to 
these findings, Cuoco et al. (34) reported that lower external loads (~ 40% of leg press 1 
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 RM) explained more of the variability in normal gait speed in the elderly than did power 
at higher external loads (~ 70% of 1 RM).  Habitual gait speed is known to be a predictor 
of future disability, thus the authors suggest that lower external resistances should be 
used when evaluating peak power in older adults (34).
 Previous cross sectional data suggest that the decline in peak muscle power with 
age is associated with muscle structure and function, tendon characteristics, and 
sarcopenia in specific muscle groups (151).  In that investigation, 169 women and 89 men 
between 18 and 88 years were studied, and muscle force and power were assessed by 
jumping mechanography.  These healthy subjects showed a difference of > 50% between 
the ages of 20 and 80 without a reduction in muscle cross sectional area suggesting that 
power declines might be a central role in the aging process.  In addition, because muscle 
power may be a better predictor than strength in predicting impaired functional ability in 
the elderly (16, 50), determining the age-related causes of decreased muscular power 
provides important and relevant information to the understanding of sarcopenia.  Bassey 
et al. (10) examined leg extensor power in elderly (~ 88 yrs old) patients in a chronic care 
facility using a custom built rig that measured maximal power output over < 1 s of a 
single extension of one leg.  Functional ability was measured by timing a standard chair 
rise, four-stair climb, and a ~ 6 m walk.  Leg extensor power was significantly correlated 
with all functional ability measures, but the functional ability measures were not 
correlated with each other except for chair rise time and gait speed.  In addition, women 
had significantly lower leg extensor power than men, but their power scores accounted 
for 86% of the variance in walking speed, which was higher than in men.  These data 
agree with recent findings that average leg extension power is a key factor that helps 
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 explain the increased prevalence of mobility impairments in the elderly (138).  More 
recent cross-sectional and longitudinal data from the BLSA (114) show age-associated 
reductions in power and isometric strength in the upper extremities in men and women 
over an average ~ 10 year period.  Peak arm power was measured in 10 - 15 sec periods 
of maximal arm cranking using a bicycle which was converted and functioned as a drive 
shaft to power a generator.  Strength and power declined beginning by age 40 in both 
women and men, but power declines were ~ 10% greater than strength losses in men, 
while no significant declines were found in women.  The differences between the changes 
in power and strength with age in men support the hypothesis that there are variables 
other than strength, such as movement velocity, that influence power reductions.  Suzuki 
et al. (170) found that ankle flexor and extensor muscle power together with self-reported 
measures of health and physical functioning were essential components of functional 
mobility in community dwelling older women.  This finding confirmed an earlier study 
by Skelton et al. (164) who found that between the ages of 65 and 89 years, power 
declines at a rate of ~ 3 – 4% per year, which is higher than the rate of isometric strength 
loss (~ 1 – 2% per year).  Runge et al. (151) also reported that there is a significant 
decrease in muscle power between the ages of 20 and 80 years, without a decline in 
muscle CSA.  Most recently, Petrella et al. (135) examined age and gender differences in 
knee extensor strength and power in young (~ 26 yr old) and older (~ 63 yr old) men and 
women.  The results showed that there were significant strength differences between the 
young and older subjects, and there was also a significant difference between age groups 
in knee extension power when normalized for thigh muscle mass.  In addition, older 
adults had a significant decrease in peak velocity over 10 repetitions of knee extension 
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 exercise, indicating that attenuation of velocity in older adults may likely be a 
contributing factor for decreases in power.  This decrease in velocity may also contribute 
to increased risk of falls and mobility loss in the elderly. 
 The mechanisms that cause a more rapid decrease in power than strength with 
aging are not yet fully understood.  However, because power is the product of force and 
velocity, variables that influence either of these two factors will have affect peak power 
(107).  Thus, many of the aforementioned mechanisms that influence muscle strength 
decline with aging are likely to also be at least partially responsible for the decreases in 
power with advancing age.  Additionally, specific changes that might influence muscle 
contraction speed will have a more significant impact on peak power than on strength.  
For example, with aging there is a preferential loss of type II skeletal muscle fiber 
number and size.  Additionally, older skeletal muscle has been shown to be more likely to 
express more than one MHC isoform than the skeletal muscle of young subjects (91).  
Animal studies report that type II skeletal muscle fibers are capable of a four-fold greater 
power and force output and a faster shortening speed than type I fibers (107).  The loss of 
type II fiber size leads to the decreased expression of fast MHC isoforms, which would 
likely have a significant impact on power output (71), and supports the evidence of 
change from fast to slow motor units with aging (189).   
 Other potential mechanisms have also been identified, which include decreased 
tendon stiffness with aging (107) and neural influences, which include dopaminergic 
neuron loss in the substantia nigra.  This could result in a decrease in coordination, 
movement speed, and power.  Furthermore, decreases in the sliding speed of actin on 
myosin with aging may play an important role in the observed power decline with 
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 advancing age.  For example, Hook et al. (74) reported an 18 – 25% age-associated 
reduction in the speed of actin filaments on myosin from 62 single fibers.  The 
mechanisms underlying the aging-related slowing of motility speed remain unknown, but 
it hypothesized that posttranslational modifications of myosin by oxidative stress, 
glycosylation, or variations in muscle protein expression might explain this decrease. 
The Effects of Strength Training as an Intervention on the Components of Sarcopenia 
 
 As a result of the increased prevalence of sarcopenia, the total health care costs 
and detrimental physical consequences that follow, it is imperative from a public health 
perspective to find a safe and effective method to increase muscle strength and mass in 
the elderly.  For this reason, interventions designed for the prevention and treatment of 
sarcopenia should positively affect muscle mass, strength, and power without adverse 
side effects.  A recent report indicates that the administration of growth hormone, one of 
the more commonly recommended interventions for sarcopenia, should not be used for 
this purpose due to its untoward side effects and questionable efficacy (18).  Therefore, 
ST should be the intervention of choice for sarcopenia due to the substantial evidence for 
its efficacy within a very short time frame and safety (47, 77, 148).  Numerous 
investigations have shown the efficacy of ST to increase muscle mass and strength in 
older adults ranging from 50 – 98 years of age (23, 47, 56, 81, 93).  Additionally, the 
muscle adaptations in the elderly with ST have been shown to improve functional 
abilities (43).   
Earlier work by Frontera et al. (56) found that ST in older men leads to increased 
strength of the quadriceps with an increase in muscle fiber size.  Since this data was 
published, numerous other investigations have been done (64, 68, 72, 81, 102, 162, 171, 
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 176, 180) showing that muscle strength increases ~ 20 to 40% in response to ST in the 
elderly.  This large range is at least partially due to study design differences.  Problems 
arise when attempting to make comparisons between different ST studies, especially with 
different outcomes.  First, studies vary greatly with regard to muscle group studied (e.g. 
upper body vs. lower body) as well as the volume (i.e. repetitions x sets) and intensity (% 
of strength) used as an intervention.  Furthermore, between-study comparisons are also 
problematic due to differences in the session frequency and duration of training 
interventions.  Some report that improvements can be seen in as few as one session per 
week (171), while others used as many as seven sessions per week (159).  The duration of 
ST interventions also vary considerably, with some lasting as little as four weeks (159) to 
almost two years (112), but most last between 8 – 12 weeks (107).  Perhaps most 
importantly, the problem with comparing studies on the effects of ST interventions in 
older adults is the differences in subjects among the various studies. These variations 
include sex differences between groups, with some studies examining one sex, while 
other studies include both men and women (107).  The ages of the study subjects can also 
vary significantly, with older subjects included ranging from those in their 50s to their 
90s.  In addition, subjects vary based on medical condition, medications, previous 
exercise experience, socioeconomic status, racial and genetic backgrounds.   
Although the majority of studies indicate that there is little age difference in 
muscle strength response to ST (86, 107), Lemmer et al. (102) reported an ~ 34% 
increase in strength in 20 – 30 year old men and women, which was significantly greater 
than the ~ 28% increase observed in 65 – 75 old subjects.  However, in that study muscle 
volume increases with ST did not exhibit these age differences.  These data suggest that 
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 in response to ST, skeletal muscle adaptations in older adults are comparable the changes 
in younger adults. 
There are three general phases that occur in both young and older subjects that are 
responsible for strength increase during a ST program.  First, during approximately the 
first two weeks of a ST program, there is a strong learning effect that improves the 
subject’s ability to perform the ST exercise.  This phase of neurological adaptation results 
in improved coordination and rapid strength gains, especially if the strength training 
modality involves a high level of skill (107).  This effect can often be attenuated by 
familiarization sessions, which can prevent observed strength gains from being inflated, 
especially in older adults.  The next phase, which occurs at weeks ~ 3 – 7, involves 
increases in muscle strength without a concomitant increase in muscle mass.  This 
improvement in strength is ascribed to continuing neural adaptations including increased 
activation of the agonist muscle group (i.e. increase motor unit (MU) recruitment and 
better coordinated MU firing), improved involvement of synergistic muscles, decreased 
antagonist muscle activation, and increased central nervous system (CNS) drive (152).  
Finally, the third phase of ST adaptations that occur at ~ 6 weeks and later results in 
increased strength along with a matching increase in muscle size. 
Muscle mass generally increases with ST in older adults, but this increase is 
dependent on the measurement tool used, the type of training program, and the age and 
sex of the subjects.  The increase in muscle mass increase is quite variable ranging from 
little or no change to a ~ 23% increase with an average increase of ~ 8% (47, 48, 56, 64).  
For example, Tracy et al. (176) measured quadriceps muscle volume using MRI at 
baseline and after nine weeks of ST in 65 – 75 year old men and women.  The results 
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 showed that there was ~ 12% increase in muscle volume.  Earlier data by Frontera et al. 
(56) reported an ~ 9% increase in the CSA of the knee extensors in a group of 60 – 72 yr 
old men who underwent a 12 week ST program, as measured by CT imaging. 
Muscle volume or cross-sectional area in current studies is usually measured by 
CT imaging or MRI.  Changes in muscle volume or CSA allows for the measurement of a 
specific muscle being trained and can differentiate between the various tissue 
components (i.e. muscle bone, and adipose tissue).  Some investigators  have  measured 
muscle volume rather than CSA to examine the changes in muscle size with ST (80, 93, 
124).  Studies that report muscle volume changes with ST often report similar or greater 
increases than CSA, leading some to suggest that muscle volume, which is a more direct 
measure of the overall muscle mass of the trained musculature, might be a more valid 
measurement option for detecting changes in muscle size with ST (177).  Despite the 
improved accuracy of the measurement of muscle size by these imaging techniques when 
compared to other methods (e.g. anthropometric methods), they are not capable of 
detecting changes in the individual muscle fibers. 
Several training studies have been done in older adults to examine the muscle 
function changes that occur at the muscle fiber level.  Data show that type I and type II 
muscle fibers in older adults maintain the ability to undergo hypertrophy with ST (30, 56, 
68, 137), but some investigations found that there was only slight or no change in fiber 
areas (64, 76).  Changes in fiber size with ST are typically at least 10%, which is 
typically greater than at the level of a whole muscle group.  This is partly because MRI 
and CT assessment of whole muscles or muscle groups also measure other tissues (e.g. 
connective tissue), which are not apt to experience the same magnitude of change as 
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 muscle tissue.  In addition, several studies have found evidence for MHC II subtype 
transformations with ST in older adults, with MHC IIb changing to IIab to IIa, which is a 
similar response that occurs in younger adults (69, 71, 158).  However, one investigation 
reported an increase in MHC I expression with ST (195), which could be attributed to a 
lower intensity training protocol in that investigation.  It has been suggested that this 
lower intensity training program was not enough of a stimulus to recruit the fast MUs 
necessary for optimal increases MHC II expression.  At the muscle fiber level, Trappe et 
al. (179, 181) found that in older men and women, skeletal muscle fibers increase in size, 
strength, and power with 12 weeks of ST.  Other investigations report increases in protein 
synthesis in older adults with ST along with improvement in strength (73, 193, 199).  
Hasten et al. (73) found that at baseline older men and women have a lower MHC and 
mixed vastus lateralis muscle protein synthesis rate than younger adults.  In addition, 
baseline actin protein synthesis rates were similar between the two age groups.  A bout of 
ST increased mixed muscle and MHC protein synthesis rates in both age groups 
indicating that contractile protein synthesis in response to an acute ST session is not 
impaired in older adults when adjusted for FFM. 
Muscle quality (i.e. strength per unit of muscle mass) has been shown to improve 
with ST in older adults (81, 176, 194).  For example, Tracy et al. (176) reported a 14% 
and 16% increase in MQ in the quadriceps in response to a nine-week ST program for 
older men and women, respectively.  More recently, Welle et al. (194) examined the arm 
and thigh muscles of older women (62 – 72 yrs) and reported that although aging might 
impair the hypertrophic response to ST, aging does not impair increases in MQ.  In that 
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 study, older women increased their knee extensor MQ by ~ 32% which was similar to the 
~ 38% change observed in younger women (194).  
 As mentioned earlier, muscle power has been shown to account for a greater 
percentage of the variance in functional abilities than strength in the elderly (16, 50).  
Furthermore, muscle power deteriorates at a faster rate than strength with advancing age 
(10, 114, 164).  For these reasons, recent studies of ST in the elderly have focused on the 
effect of ST on muscle power (15, 37, 41, 46, 49, 68, 86).   
A randomized study by Earles et al. (41) compared the effects of a high-velocity 
ST program combined with moderate non-resistive exercise to an intervention of walking 
on leg press and knee extension peak power in men and women over the age of 70.  
Power improved significantly in the high-velocity ST group only for leg press (22%) and 
knee extension (increases of 50%, 77%, and 141% when power was tested at external 
resistances of 50%, 60%, and 70% of body weight, respectively).  However, these 
improvements in power did not lead to improvements in functional abilities, although 
their cohort was considered high functioning at baseline.  A more recent randomized 
study by Fielding et al. (49) examined 30 older women with mild functional limitations 
and compared the changes in skeletal muscle power between 16 weeks of high-velocity 
ST and a more traditional, low-velocity ST intervention.  The results indicate that 
although leg press and knee extensor 1 RM strength increased similarly in both groups 
with ST, leg press peak power increased significantly more in a high-velocity group 
(97%) than in a low-velocity group (45%).  The conclusion was that higher-velocity 
training programs might be more efficacious for increasing peak power in older 
individuals with functional impairments.  However, it is still not well established whether 
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 a high velocity training program is well tolerated by older subjects (44), especially 
subjects who are frail and could benefit the most from increased muscle power.  Most 
studies that examined peak power used lower-velocity ST protocols that have extensive 
track records for being generally safe for older subjects (48, 86, 166).  In these 
investigations, muscle power increased significantly with ST, ranging from ~ 18 – 28%, 
although the increases in strength were greater due to specificity of training.  
In an earlier investigation, Fiatarone et al. (48) conducted a randomized, placebo-
controlled trial comparing ST, multinutrient supplementation, both interventions, and 
neither in 100 frail nursing home residents over a 10-week period.  Power, as measured 
by stair-climbing performance improved in the exercise group compared with the non-
exerciser group (28.4% vs. 3.6%).  These data indicated that there is a relationship 
between power adaptations to ST and functional ability.  That study was followed by a 
report by Skelton et al. (166), who found that in 20 relatively healthy, independent 
elderly (76 to 93 years) women, knee extension power increased by 18% (as measured by 
the Nottingham Power Rig developed by Bassey and Short (12)) when adjusted for body 
weight.  More recent data reported by De Vito et al. (36) examined the effects of a 12 
week of a low-intensity general conditioning program on maximal power in 20 elderly 
women (~ 63 yrs) randomized to a training or control group.  Peak power was determined 
at baseline and after the training regimen via vertical jump on a force platform.  Peak 
power increased significantly in the training group, but did not change in the control 
group.  The authors suggested that this increase in power could be due to improvements 
in neuromuscular activation.  Additionally, Jozsi et al. (86) reported that with ST in men 
and women age 56 – 66 years,  there was an increase in knee extensor and arm flexor 
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 power with ST of 30% and 18%, respectively.  These increases in peak power were 
independent of age or sex and occurred at 40% and 60% of 1 RM, and were similar to the 
changes observed in younger subjects.  Izquierdo et al. (82) also reported that 16 weeks 
of ST resulted in large gains in strength and power load characteristics of the upper and 
lower extremity musculature, but the pattern of strength and power development seemed 
to differ between the upper and lower extremities in middle aged and older men.  These 
studies, when taken together, suggest that both traditional and higher-velocity ST 
interventions are capable of increasing muscle power in older adults. 
As mentioned earlier, one of the problems with muscle power testing is the 
difficulty in safely and accurately measuring power (107).  Previous investigations (41, 
49, 82, 86) reported peak power as the highest average power obtained during multiple 
trials of a power test, as opposed to the highest power value attained during a single trial.  
The highest peak power (i.e., the highest combination of force and velocity that occurs 
simultaneously during a single trial) might be a more accurate measure of the explosive 
capacity of the trained musculature than average (area under curve) power of a single 
trial.  This is because average power includes two phases of movement that represent 
reduced power.  The first is at the beginning of the movement when one is trying to 
overcome inertial forces and the other is near the end of the movement when co-
contraction of the antagonist muscle group produces a reduced force and velocity.  
Although some previous investigations did exclude data from the first and last 5% of the 
range of movement in the power tests (16, 49, 50), these studies still used the average 
power for a given trial, and reported it as peak power.   
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 Furthermore, these earlier reports (41, 49, 82, 86) on the effects of strength 
training (ST) on muscle power also did not report how the training affected power per 
unit of the muscle involvement (muscle power quality, MPQ), or peak movement 
velocity (PV), the latter possibly being an important component of power and possibly 
functional abilities in the elderly.  The expression of peak power and PV normalized for 
muscle volume allows better understanding of potential mechanisms (e.g., hypertrophy 
and neuromuscular adaptations) for training-induced adaptations.  It is also important 
when comparing groups who possess different amounts of muscle mass, such as men 
compared to women.  Most recently, Delmonico et al. (37) reported the effects of a 10-
wk, moderate velocity ST intervention on peak knee extensor power in relatively healthy 
older men (n = 30) and women (n = 32).  Results showed that peak power (PP) increased 
significantly in both men and women at the same absolute (same absolute resistance 
before and after ST) and relative (70% of 1 RM at baseline and 70% of the improved 1 
RM after ST) external loads.  In addition, men and women both increased their absolute 
peak movement velocity with ST, and there was a significant 9% training-induced 
increase in MPQ in women, but no change in men.  This latter finding indicates that 
women may not rely on muscle hypertrophy as much as men to improve muscle function 
with training.  This could possibly be due to some type of neuromuscular adaptation that 
compensates for the reduced capacity of women to undergo muscle hypertrophy with ST 
compared to men, resulting in a compensatory increase in power per unit of muscle.  
Support of a sex difference in MPQ comes from work by Trappe et al. (179, 181) who 
found that the response of skeletal muscle fibers to ST on peak power normalized for cell 
size and unloaded shortening velocity differ with the same training stimulus between men 
 116 
 and women.  However, no change in muscle fiber unloaded shortening velocity or 
normalized peak power was found in older women, indicating a sex difference in 
response to ST, although the cause for this difference is unclear. 
Muscle power is a more complex phenotype than strength, thus there may be 
more interrelated factors that influence peak power changes with ST than are responsible 
for muscle strength changes alone.  First, there are possible preferential increases in type 
II fibers leading to overall increases in muscle mass, which in turn leads to enhanced 
force production and muscle fiber shortening (49).  Previous data has shown that 
adaptations to single MUs can help increase contraction speed with ST (187).  Changes in 
MU function consist of earlier activation, shorter interspike intervals, and increased 
maximal firing rate (187).  In addition, neural adaptations, including increased activation 
of the agonist muscle groups, decreased co-activation of the antagonist muscle groups, 
improved coordination and activation of synergistic muscles, and increased neural drive 
from the CNS, might lead to improvement in power with ST (107).  Nevertheless, it may 
be problematic to directly examine these potential neurological components during power 
testing using electrophysiological methods because there are a host of physiological, 
mechanical, and electrical changes that happen during the contraction that might impact 
the correlation between signal amplitude and muscular force (107).  Finally, tendon 
stiffness may be affected by ST, which may affect power changes.  Maganaris et al. (109) 
used an in vivo method for assessing tendon stiffness in older adults, and found that 
patellar tendons stiffened structurally and materially by ~ 65% in response to a 14-week 
ST intervention.  The rate of muscle torque production also increased by ~ 27%, 
indicating that there is a faster contractile force transmission to the skeleton.  These data 
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 provide support for several mechanisms that might play a role in the changes in power 
with ST.  However, there appears to be a great deal of inter-individual variability in the 
rate of decline in muscle mass and muscle function with aging (111).   
Variability in Muscle Size and Function in Response to Aging and Strength Training  
Muscle mass, strength, and power responses to ST vary substantially among 
individuals.  In a previous investigation from our lab, after only nine weeks of a highly 
standardized quadriceps strength training program in a healthy and homogeneous group 
of 65 to 75 year old men and women, there were observed knee extension strength gains 
that ranged from 5 to 86 pounds (80).  Others have also observed large variations in 
strength and muscle mass changes with ST (26).  They reported one repetition maximum 
(1 RM) strength increases that ranged from 1 to 50 kg after 20 weeks of ST.  The 
standard deviations of the changes were larger than the mean changes and the coefficients 
of variation (CV) were > 100 %.  In addition, muscle power changes with ST also are 
quite variable, as data from our lab indicates that changes with ST of the knee extensors 
for men and women in peak power range from – 19 to 126 W at the same absolute 
resistance, and peak movement velocity changes ranging from -1.1 to 2.7 rad/sec at the 
same absolute resistance (37).  These data indicate that there are large inter-individual 
variations in strength changes even in response to very short term, highly standardized 
strength training interventions.  Studies here have also reported increases in quadriceps 
muscle volume with ST that range from 19 to 344 cm, further demonstrating the wide 
variation of inter-individual changes in muscle mass from ST (80).  These large inter-
individual differences among older men and women are consistent with the possibility 
that genetic factors are involved in determining muscle strength, muscle mass, and 
 118 
 muscle power responses to strength training.  This large inter-individual variability and 
the fact that twin studies show that a major portion of the variance in strength and muscle 
mass can be accounted for by heredity, suggest that heredity and specific gene 
polymorphisms may explain a large portion of inter-individual differences in responses to 
ST. 
Heritability of the Components of Sarcopenia   
The estimation of heritability of a specific trait is commonly estimated by the 
study twins and families.  The most common analysis of heritability is phenotype 
measurement between and among sets of monozygotic and dizygotic twins.  If a trait is 
completely determined by genetics, there would be correlation of 1.00 between sets of 
monozygotic twins, but a correlation of only 0.50 between dizygotic twins because 
dizygotic twins only share ~ 50% of their genetic makeup.  However, skeletal muscle 
phenotypes are also influenced by many other factors beyond genetics, which can have an 
effect on the heritability estimate.  Factors such as shared/non-shared environmental 
factors, additive/dominant genetic effects, and measurement error can influence these 
heritability estimates (22).   
Evidence from heritability studies suggest that many skeletal muscle-related 
phenotypes, including strength, fat-free mass (FFM), and skeletal muscle fiber 
composition are at least partially explained by genetic factors.  Twin studies indicate that 
strength has a moderate to high heritability, with different studies reporting a range of 30 
– 80% depending on the population studied.  For example, Frederiksen (52) reported that 
in 1,757 Danish twin pairs aged 45 - 96 years, that handgrip strength heritability is 52% 
and is as high as 62% when examining only healthy twin pairs from the cohort.  Grip 
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 strength has been shown to correlate strongly with other muscle groups with respect to 
strength and power.  Men and women were used in this analysis and age was stratified 
into quartiles in the model.  Results further indicated that a large portion of the variance 
is explained by additive genetic effects and non-shared environmental factors.  In 
addition, there was no significant influence of age or sex in this analysis, indicating that 
these variables were not confounders or effect modifiers in this study.  This heritability 
estimate is higher than previous data from postmenopausal female twins (6) that indicate 
a heritability estimate of 30%.  Moreover, because of the evidence for heritability of grip 
strength, and because grip strength has been previously shown to be predictor of overall 
muscle function (140, 141) and subsequent disability (142), measurement of grip strength 
in future investigations on sarcopenia is justifiable.  Other data on strength in older male 
twins indicated that a heritability of 65% at baseline, but when shared environmental 
factors were included in the model, this estimate dropped to 35% (29).  A 10-year follow 
up indicated a heritability estimate of only 22% (29).  More recently, Tiainen et al. (174) 
indicated that handgrip and knee extension strength share a common genetic component, 
accounting for 14% of the variance in older female twins.  Furthermore, additive genetic 
effects accounted for 46% of the variance in knee extension strength.   
Although there is currently not enough data to conclusively state what the 
heritability is for the loss of muscle power with aging, recent evidence suggests that knee 
extensor strength and power share a common genetic component (174).  Data from the 
Finnish Twin Study on Aging, examined the genetic component of maximal voluntary 
knee extension power and strength in 101 monozygotic (MZ) and 116 dizygotic (DZ) 
female twin pairs aged 63 – 76 yr (175).  Results indicate that a common genetic factor 
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 accounted for 32% of the total variance in leg extensor power and only 4% of the 
variance in power is attributable to non-shared environmental factors.  Additional 
evidence from twin studies on younger subjects indicate that the heritability of muscle 
power is 0.84 from a 5s Wingate cycle test (27).  Many more studies will need to be done 
in order to more accurately determine the heritability of the explosive type of skeletal 
muscle power and the heritability of its decline with aging.   
Muscle mass has also been investigated with regard to heritability using family 
and twin studies and it has been shown that estimates range from 50 – 80%.  Data from 
an inbred founder population (Hutterites) with detailed family pedigree records indicates 
that FFM is highly heritable (h2 = 0.76) (1).  In addition, Arden (6) indicated that in 
postmenopausal women, FFM has a heritability estimate of 56% when height and weight 
are covaried.  This is somewhat lower than what Seeman et al. (156) reported in younger 
female twins, who found that FFM is ~ 80% due to genetic factors.  This corresponds to 
data that shows FFM is the phenotype that is most similar between girls and their parents 
when compared to % fat, total body mass, and BMI (183).  In addition, the estimation of 
FFM values has been shown to correlate more strongly among relative than among 
unrelated individuals (20).  More recent twin data confirm these estimates, finding a 
heritability estimate of 77% for FFM in both men and women (70).  Again, age and sex 
do not appear to be significant covariates of within pair differences.  With regard to 
skeletal muscle fiber composition, earlier heritability estimates suggest that muscle fiber 
type composition is over 90% genetically determined (92), but later studies indicate it is 
only around 45% (161).  Furthermore, skeletal muscle enzyme activity also seems to be 
somewhat heritable, with estimates of 25 – 50% when adjusted for age and sex (21).  In 
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 order to more fully understand the specific contribution of specific gene variants toward 
explaining muscle phenotypes, an additional approach is to identify biologically plausible 
genes and conduct a candidate gene association study.  
Candidate Genes for the Components of Sarcopenia 
There have been relatively few candidate genes that have been consistently 
associated with skeletal muscle phenotypes and human performance.  The angiotensin-
converting enzyme gene (ACE) seems to be the most promising candidate gene to explain 
individual variation in skeletal muscle phenotypes.  ACE is the most studied gene with 
regard to exercise related phenotypes, and has also been widely studied with respect to 
other pathophysiologic phenotypes, including CHF, essential hypertension, diabetic 
kidney disease, and CHD (13).  Within the ACE gene, there have been several 
polymorphisms discovered with the insertion/deletion (I/D) polymorphism, a 287 bp 
insertion or deletion of an Alu element in intron 7 being the most widely studied 
polymorphism in this gene.  The ACE I/D polymorphism has been shown to perhaps 
explain ~ 50% of the variance in ACE levels (13).  The D allele has been associated with 
higher ACE levels in a dose-dependent manner, with the D homozygotes having the 
highest ACE levels, followed by I/D genotype, with the I homozygotes displaying the 
lowest levels of ACE activity.  This has been consistently shown despite the fact that this 
polymorphism is not found in a coding region of the gene.  The I/D polymorphism is very 
common in the Caucasian population, with genotype frequencies of 25%, 50%, and 25% 
for the I/I, I/D, and D/D genotypes respectively.  The allele frequencies from the limited 
African-American data suggest that the D allele is substantially higher in this population 
with a frequency of approximately 70% (9). 
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  Data from numerous cross-sectional investigations show that there is some 
evidence that ACE plays a significant role in various phenotypes, including skeletal 
muscle.  Aerobic testing data has found that in post menopausal women, I homozygotes 
carriers have a greater increase in the a-vO2 difference during maximal exercise testing 
(66).  The a-vO2 difference might be considered more of an intermediate phenotype than 
VO2 max and also a better indication of skeletal muscle metabolism.  Myerson et al. (125) 
examined the distribution of the I/D polymorphism in elite (mostly Caucasian) track 
athletes and found that there was a significantly higher I allele frequency in endurance 
athletes.  This corresponds to previous data (59) that also found a significantly higher 
frequency of the I allele among elite Australian rowers who were aerobically trained.  
Nazarov et al. (127) also reported that there is a higher proportion of Russian track & 
field athletes and swimmers who engage in events of greater than one minute who also 
have the I allele.  Furthermore, Woods et al. (196) reported that there is a higher 
frequency of the D allele among sprint swimmers when compared to swimmers who 
compete in longer duration events.  Despite these compelling data, not all reports agree.  
At the skeletal muscle fiber level Zhang et al. (203) reports that muscle fiber area is 
associated with ACE I/D genotype in a dose-dependent manner (DD > ID > II).  Thomis 
et al. (173) found no association at baseline between this polymorphism and muscle 
torque, strength, or cross-sectional area in 33 pairs of Caucasian twins.  Folland et al. (51) 
also reported no association between the ACE I/D genotypes and muscle strength at 
baseline in young sedentary males.  Although these studies are not all in agreement and 
these study designs (cross-sectional) do not allow causal inference.  Taken together, 
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 however, they do suggest that there may be an underlying mechanism for the ACE I/D 
polymorphism and an effect on performance. 
 In addition to the numerous cross-sectional studies that have been reported with 
regard to the ACE I/D polymorphism, training studies provide additional information on 
the potential effects of the ACE I/D polymorphism and allow for insight as to whether or 
not there is a gene-exercise interaction.  The data regarding aerobic exercise training and 
the association between the I/D polymorphism and various skeletal muscle phenotypes 
have been inconsistent.  Montgomery et al. (121) reported that arm endurance is more 
improved in I homozygotes when compared to D allele carriers.  Moreover, the delta 
efficiency ratio (work performed divided by work expended), a strong indicator of 
skeletal muscle efficiency, has been found to increase only in I homozygotes.  
Montgomery et al. (120) also noted that after 10 wks of aerobic exercise training, that I 
homozygotes show a greater anabolic response to training, showing increases in fat mass 
and fat-free mass compared to the other genotypes.  This might represent greater 
metabolic efficiency of substrate use as perfusion of skeletal muscle and other oxidative-
favoring changes in skeletal muscle have been shown to occur with decreased ACE 
levels.  These data are in contrast to the findings of Um et al. (184) who found that there 
was no association between the ACE I/D genotype and BMI among Korean women.  
However, this was not a training intervention study.  In addition, Folland et al. (51) found 
that there was a greater increase in strength among D allele carriers with ST, and this 
again followed a dose-dependent pattern (DD > ID > II).  Not all studies agree with these 
findings, as Thomis et al. (173) found no association between the I/D polymorphism and 
muscle cross-sectional area, strength, or torque among genotype groups.  In fact, a trend 
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 toward increase flexion torque was noted among I homozygotes, which was not expected 
based on previous findings.  Furthermore, Sonna et al. (167) found that in US army 
recruits that there was no association between vigorous exercise training-related 
phenotypes and the ACE I/D polymorphism.  However, it should be pointed out that the 
training regimen was mixed (endurance/strength) and the measures of muscle strength 
were questionable as their efficacy to measure peak strength.  Taken together, these 
training data do suggest that there may be a gene-exercise interaction with respect to the 
ACE I/D polymorphism. 
 In addition to ACE being a promising candidate gene for explaining the inter 
individual variability of skeletal muscle phenotypes, there are other candidate genes that 
have demonstrated a consistent relationship for predicting phenotypic variation.  First, the 
vitamin D receptor (VDR) gene is a potential candidate for skeletal muscle phenotypes, 
including gene-exercise interactions.  Although a great deal research has been done 
examining the association between VDR polymorphism and bone mineral density, there 
recently have been reports linking certain polymorphisms of the VDR gene with muscle 
strength and sarcopenia (65, 150).  In elderly women, a significant difference in 
quadriceps strength was observed between the bb and BB genotype of the VDR BsmI 
polymorphism (60).  Other investigations have found an association between FFM and 
the FokI polymorphism of VDR (150), while others found no association between this 
polymorphism and muscle strength in older adults (188).  Although many more studies 
need to be done, the majority of the evidence suggests that VDR gene polymorphisms 
play a role in the determining the training response to ST with regard to various skeletal 
muscle phenotypes.   
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  Another potential candidate gene is the insulin-like growth factor-2 gene (IGF2), 
as IGF II has been shown to have proliferative effects in adult skeletal muscle and is one 
of the major hormones for fetal growth.  The ApaI polymorphism has been recently 
studied with regard to its effects on strength and muscle mass, and has shown mixed 
results.  In an investigation by Sayer et al. (154) that examined 693 British men and 
women, the ApaI genotype was found to be a significant predictor of adult grip strength 
in men after adjustment for age and height, but these associations were not seen in 
women.  However, the ApaI polymorphism does not appear to explain the association 
between size at birth and future grip strength.  This data is complemented by recent 
longitudinal data by Schrager et al. (155) who reported lower isokinetic arm strength in 
men who are A homozygotes at the ApaI polymorphism when compared to the G/G 
group.  Women who were A homozygotes have less total body FFM when compared to 
G/G women, and have lower isokinetic arm and leg strength at baseline, and at age 35 for 
each phenotype.  These differences between the genotype groups are maintained at age 
65 and across the adult age span.  These results support the hypothesis that ApaI 
polymorphism may influence developing muscle and may affect muscle mass and muscle 
function in later life. 
 In addition, there are other candidate genes that have been suggested as 
candidates for explaining phenotypic variation in skeletal muscle, but have not been 
studied as extensively.  Ciliary neurotrophic factor (CNTF) appears to be another 
candidate gene that could potentially have an effect on peak muscular power with aging 
as CNTF has trophic effects on muscle tissue by functioning as a maintenance and repair 
factor for adult motor neurons (95, 149).  A single nucleotide polymorphism (SNP) at this 
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 locus results in a G-to-A transition, which produces a new splice acceptor site and the 
results in an atypical protein (172).  A recent investigation that examined the association 
between peak torque, muscle quality, and this SNP showed that heterozygotes had 
significantly greater knee extensor and flexor peak torques during isokinetic testing at 
higher velocities (3.14 rad/sec) than G homozygotes (149).  It has been shown that there 
is a strong correlation between isokinetic strength at high velocities and knee extensor 
power (88), which suggests that this polymorphism may also influence peak power. 
 Tumor necrosis factor-alpha (TNF), also known as CACHECTIN, DIF, TNFA, 
and TNFSF2 seems to also be an interesting candidate gene with regard to its potential 
role for influencing muscle phenotypes.  TNF-α, a cytokine, is reported to be involved in 
numerous biological processes including cell proliferation, differentiation, and mediating 
muscle wasting (97).  TNF-α has also been associated with a variety of diseases, 
including autoimmune diseases, insulin resistance, and cancer.  Mouse data indicate that 
TNF-α is involved in the recovery of muscle function after traumatic muscle injury, as 
mice that are TNF-a deficient exhibit strength deficits twice that of wild-type mice 
following freeze injury to skeletal muscle (192).  However, with ST in elderly subjects, 
both TNF-α mRNA and protein levels were decreased, indicating attenuation of age-
related muscle wasting (63).  This data is confirmed by more recent evidence in very 
elderly subjects, who experienced low-grade inactivation of the TNF-α system following 
ST (25).  There are SNPs that have been identified at the TNF locus that may be worthy 
of investigation, such as the G-308A SNP in the promoter region that have been reported 
to influence the expression of TNF-α (153). 
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  These candidate genes have been identified as being at least partial contributors to 
the inter-individual variation observed in skeletal muscle phenotypes.  While the 
influence of various polymorphisms at multiple gene loci has been examined, many more 
studies are needed to identify the genetic basis for the variability of complex phenotypes 
such as skeletal muscle.  Identification of the specific gene variations, gene x gene 
interactions, and haplotypes that influence this variability is important for clinical 
applications for eventually allowing for individualized exercise prescriptions based on a 
genetic predisposition for sarcopenia.  Recent attention has focused on the alpha-actinin-3 
(ACTN3) gene, which has been called the “gene for speed” by some (108).  A more 
thorough examination of the influence of this gene may give insight regarding these inter-
individual variations in response to ST.    
ACTN-3 and the ACTN3 R577X Polymorphism 
Alpha-Actinins (ACTNs) are cellular proteins that are encoded by the spectrin 
superfamily genes that are distinguished by their ability to bind actin (39).  ACTN 
isoforms have been observed over a broad variety of taxa, which include protists, 
invertebrates, birds, and mammals.  As a result of both gene duplication and alternative 
splicing during the course of evolution, substantial functional variety has resulted with 
regard to the ACTN family (108).  Antiparallel ACTN dimers have actin cross-linking 
activity and bind with actin, as well as preserve a spatial association among myofilaments 
(131).  The binding ability of ACTNs to actin is due to the presence of two N terminal 
calponin-homology domains in the ACTN protein.  The existence of calcium-sensitive 
EF (elongation factor) hands at the C-terminus of the ACTN allows for the release of 
actin from ACTN.  ACTN proteins are present in both non-muscle and muscle tissues, 
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 with its purpose in skeletal and cardiac muscle being the primary constituent of the Z-
disks of the sarcomere, forming a lattice arrangement anchoring together the actin (thin) 
filaments and helps to stabilize the muscle contractile structure.  Additionally, four 
different isoforms of the ACTN protein have been identified (39).  Of these, ACTN-2 and 
ACTN-3 are present in striated muscle, with the latter being present only in skeletal 
muscle (17).  
 Evidence suggests that ACTNs are essential proteins with regard to maintenance 
of muscle structure, contraction, and connection of the sarcomere to the plasma 
membrane.  In addition, ACTNs may also play a critical role in intracellular signaling 
between the sarcomere and metabolic pathways with regard to skeletal muscle 
metabolism (108). 
 A host of proteins have been shown to interact and bind with ACTNs, although 
most of the evidence is from ACTN-2 data.  However, due to the high sequence 
similarity between the two isoforms, it is suggested that similar interactions exist for 
ACTN-3, as well.  It appears that ACTNs bind high affinity to each other, via interactions 
involving their spectrin-like repeats (SLRs, 1-4) that form homo- and heterodimers.  
Formation of dimers allows for a long molecule that has an actin binding domain (ABD) 
at the end that allows for cross-linking of actin, and it permits the C-terminal region of 
one of the ACTN molecules near the N-terminal ABD of the other molecule, facilitating 
interactions of the two areas (108).  These appear to be similar in affinity and stability 
that implies functional resemblance between the two dimers. 
 Another category of proteins that bind to ACTNs include structural proteins of the 
muscle contraction apparatus.  The most highly studied binding partner of these proteins 
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 is actin.  In addition, ACTNs also bind with myotilin, an actin cross-linking protein, as 
well as with titin, nebulin, and CapZ, a filament capping protein.  ACTNs are also 
involved in two of the protein structures that attach the sarcomere to the plasma 
membrane, via interactions with dystrophin and integrin (108). 
 In addition to the structural and contractile relationships between ACTNs and 
various striated muscle proteins, ACTNs also interact with a host of signaling proteins as 
well as with membrane receptors and ion channel proteins.  Furthermore, ACTNs have 
been reported to interact with calsarcin proteins, which are found at the Z-line and bind to 
calcineurin (53).  Calcineurin, a signaling protein, is postulated to play an important role 
in hypertrophy and fiber type determination.  Interaction between ACTNs and metabolic 
enzymes also has been reported, but the meaning of these interactions is unknown (61).  
However, the presence of metabolic enzymes (e.g. F-1,6-BP) at the Z disk held by 
ACTNs might add to the local accessibility of necessary metabolites for production of 
energy (108).   
 Earlier data suggested that a deficiency of ACTN-3 expression is linked to 
merosin-positive congenital muscular dystrophy (CMD) (130).  Evidence from muscle 
biopsies indicated that ~ 25% of subjects with merosin-positive CMD were ACTN-3 
deficient, but it was not clear from this data whether or not ACTN-3 deficiency was due 
to a mutation(s) in ACTN-3 or is a secondary marker.  Later biopsy data (186) from 
subjects with various forms of MD showed that subjects from the same families and with 
the identical disease were discordant for ACTN-3 deficiency, and it was concluded that 
ACTN-3 deficiency is only a secondary effect in the various forms of MD.  Thus, a 
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 deficiency of ACTN-3 doesn’t seem to lead to a disease phenotype, as the ACTN-2 
isoform may help compensate, but this compensation may not be complete. 
          ACTN-2 expression occurs in all skeletal muscle fiber types, but ACTN-3 
expression is restricted to type 2 fibers (131).  ACTN3 is located on chromosome 11 
(11q13-q14), spans ~17 kbp, and contains 21 exons.  A previous investigation identified a 
single nucleotide polymorphism (SNP) along exon 16 of the ACTN3 gene when 
investigating congenital muscular dystrophy and a complete absence of ACTN-3.  This 
SNP results from a C to T transition at position 1,747 that results in a change in the 577 
residue from arginine to a premature stop codon (R577X) (131).  Homozygosity of 
R577X results in an absence of ACTN-3 expression, although the individuals affected 
typically appear phenotypically normal.  Investigations of various populations estimate 
that approximately 19% of Caucasians are ACTN-3 deficient, indicating that this SNP is 
non-pathogenic and in humans is likely redundant (119). 
      The absence of ACTN-3 due the R577X SNP has raised questions regarding the 
subtle potential effects on athletic performance.  Since ACTN-2 and ACTN-3 are roughly 
90% similar and ACTN-2 entirely overlaps ACTN-3, some have speculated that due a 
functional redundancy, no observable changes in athletic performance would likely occur 
in the ACTN-3 deficient individuals as ACTN-2 would have a compensatory effect 
(119).  Nonetheless, ACTN-2 and ACTN-3 are differentially expressed indicating that 
ACTN3 continues to be highly conserved in the genome (119).  In this regard, recent 
cross-sectional data suggests that a deficiency of ACTN-3 is associated with an 
enhancement of athletic performance.  Zantoneli, et al. (202) reported that when vastus 
lateralus muscle biopsies from elite marathon runners were examined for muscle fiber 
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 type ratios and ACTN isoforms, one out the six had a complete deficiency of ACTN-3.  
This deficiency was not related to a lack of type II fibers suggesting that ACTN-3 is 
redundant and may actually impede endurance performance, although no information was 
provided by the authors if this was a statistically significant finding and what the 
potential mechanism for increased performance is.  In support of this data, Yang (198) 
genotyped 429 unrelated elite Caucasian athletes (men and women), as defined by 
competition at the international level.  Control subjects (n = 436) were also genotyped.  A 
subset of the cohort (n = 107) was created and represented athletes who competed in 
power-related events such as sprinting, as well as a subset of 194 endurance athletes to 
make the groups homogenous.  Chi-square analyses revealed that the power athletes had 
a significantly lower frequency of the X homozygotes when compared to controls and a 
higher R homozygote frequency.  In addition, there was a difference between the power 
and endurance athletes with respect to the X homozygote frequency, which explained 
why the athlete vs. non-athlete analyses showed no difference in genotype/allele 
frequencies.  The case-control design of the Yang study (198), has limitations particularly 
when assessing gene-exercise interactions, because all subjects were grouped by event 
type or athlete/non-athlete and no measures were made to quantify performance or 
changes in performance.  However, this data was recently confirmed by a recent report 
that examined the R577X polymorphism in elite Finnish sprint (n = 89) and endurance (n 
= 52) athletes (129).  The results show that the frequency of the XX genotype is 
significantly higher and the RR genotype is lower in these endurance athletes.  In 
addition, none of the sprinters were X homozygotes, which supports the hypothesis that 
this polymorphism confers an athletic performance advantage. 
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  More recently, the first intervention study was done to assess the effects of the 
R577X polymorphism on changes in muscle strength with ST (31).  In that investigation, 
602 young adults (247 men & 355 women) of diverse racial backgrounds were tested at 
baseline for maximal voluntary isometric contraction (MVC) and 1 RM strength of the 
elbow flexors at baseline and after ~ 12 weeks of ST with the non-dominant arm.  
Magnetic resonance imaging (MRI) was done on each subject’s arm to determine the 
baseline cross-sectional area (CSA) and change in the CSA with ST.  Analyses of 
covariance (ANCOVAs) within each sex by ACTN3 R577X genotype found that there 
were no differences in men by genotype group for baseline MVC, 1 RM, or CSA.  In 
addition, there were no changes with ST by genotype group for these muscle function 
measures.  In women, there was significantly greater (~ 13%) baseline MVC in the RX 
group than the XX group, but no difference in baseline 1 RM.  Furthermore, the data 
showed that there was a significantly greater increase in 1 RM strength in the XX group 
than in the RR group, and there is evidence of a dose-response relationship based on the 
number of X alleles present.  Additionally, the data indicate that the ACTN3 R577X 
polymorphism explains ~ 2% of the variance in baseline MVC and change in 1 RM 
strength in women.  One possible explanation for these unexpected results given by the 
authors was that there were lower initial values in the XX group and thus there was a 
greater potential for increase with ST.  Another explanation given was that there is less 
stability and greater disruption of the Z-disk in X homozygotes, which makes the muscle 
more easily stimulated with eccentric contractions to form new sarcomeres, leading to 
greater strength increases.  This explanation is not supported by follow-up data from this 
same cohort (32), which showed that there was no influence of ACTN3 R577X genotype 
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 on plasma creatine kinase (CK) or myoglobin (Mb) with eccentric exercise.  These data 
refute the explanation that structural differences between ACTN-3 deficient muscle and 
normal muscle influence muscle damage with eccentric exercise.  Finally, the sex 
differences in baseline MVC and 1 RM strength response by ACTN3 genotype were 
explained by the fact that women have lower baseline values and their percent increase 
was greater than in men, making the detection of differences by genotype easier.  
Furthermore, the hypothesis that steroid hormone differences might be at least partially 
responsible for the sex differences observed by ACTN3 genotype, as steroid hormones, 
might mask the subtle effect of the ACTN3 R577X polymorphism on skeletal muscle 
function measures.  However, there were limitations to this investigation.  First, the 
measurement of biceps CSA did not employ the use of bony landmarks for MRI 
scanning, rather soft tissue landmarks were used, which are subject to testing error and 
can actually change with ST.  Furthermore, the use of 1 RM and MVC may not be the 
most appropriate tests to determine the true influence of the ACTN3 R577X 
polymorphism on muscle function.  A test that employs faster speed of contraction and 
peak power would likely be a better measurement to examine the effect of this 
polymorphism on muscle performance.      
In summary, sarcopenia is associated with loss of functional abilities, and 
increases in morbidity and mortality rates in the elderly (140, 141).  Studies indicate that 
the approximate age-associated decline in strength is 20 – 40% when young subjects are 
compared to those in their 70s or beyond (98, 200).  The actual decline in the entire 
population may even be greater than the decline indicated by various investigations, 
because older individuals may not be adequately represented in these studies due to the 
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 presence of disease (160).  Men have a greater absolute decrease in strength than women, 
but initial values are higher in men (19, 35, 190).  As a result, men retain a higher 
absolute amount of muscle strength than women, even after aging-related losses.  Starting 
with a lower absolute value combined with the fact that their life expectancy is greater, 
women are considered to be more susceptible to sarcopenia and long-term disability than 
men (100).  Furthermore, strength tends to peak in the 30s, then remains stable until the 
50s, then declines at a rate of ~ 10 – 15% per decade (55, 98, 104).  This reduction is at 
least partially due to a decline in force production by muscle fibers.  The decrease in 
power observed in older adults with aging is typically greater than the declines in strength 
and may be an independent predictor of mortality (117).  However, data indicate that 
thigh muscle composition, strength, and body fat mass are important contributors to peak 
power production in the lower limbs in older adults (163).  This decline in peak power 
appears to be a better predictor of impaired functional capacity than strength (165) and is 
influenced by other factors besides loss of muscle mass.  There are numerous adaptations 
that influence the muscle adaptations to ST, and many of these adaptations that improve 
muscle size and strength are known to affect muscle power.  However, some of the 
specific mechanisms that lead to increases in muscle power with ST are still unclear.  
However, interventions specifically designed to optimally improve muscle power have 
not been established and their safety often questionable.  Studies that examined the effect 
of ST on muscle power in older adults often show inconsistent results.  These 
discrepancies are likely to be at least partially due to inter-individual variability in the 
rate of decline in muscle mass and muscle function with aging, and variation in response 
to ST (111).  Some of this inter-individual is likely due to genetic factors as twin and 
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 family studies indicate.  In addition, several candidate genes have been identified that are 
hypothesized to explain part of the inter-individual differences observed in skeletal 
muscle phenotypes.  The ACTN3 R577X polymorphism is functional and has been shown 
to be a strong candidate gene to explain inter-individual differences in skeletal muscle 
phenotypes, especially muscle power.  This is based on its pattern of expression in type II 
skeletal muscle fibers, which are known to be specific for the generation high movement 
velocities and greater force production than type I muscle fibers.  However, many more 
studies will need to be done in order to fully understand the contribution of this 
polymorphism to the variability of skeletal muscle phenotypes. 
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